

OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF

FIELD OF THE INVENTION

Promoter sequences of the optineurin gene can be used to diagnose, prognose, and treat glaucoma and related disorders. Methods, kits, and nucleic acids capable of
5 detecting or containing polymorphisms located within the promoter region of the optineurin gene are also provided. The promoter sequences can also be used to generate cells, vectors, and nucleic acids useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions and methods.

BACKGROUND OF THE INVENTION

10 The glaucomas are a group of debilitating eye diseases which represent the leading cause of preventable blindness in the United States and other developed nations. Approximately 2.47 million people in the United States and over 67 million people world-wide are estimated to be affected with glaucoma, and over 100,000 Americans are expected to develop this condition every year. Quigley and Vitale, *Invest. Ophthalmol.*
15 *Vis. Sci.* 38:83 (1997); Quigley, *Br. J. Ophthalmol.* 80:389 (1996). Glaucoma is a progressive optic neuropathy characterized by a particular pattern of visual field loss and optic nerve head damage resulting from a number of different disorders that affect the eye. In general, glaucomas are characterized by degeneration of the optic nerve.

Primary Open Angle Glaucoma (POAG), the most common form of glaucoma, is
20 characterized by cupping of the optic nerve head, an altered visual field, and an open

iridocorneal angle. Approximately one-half of patients with POAG have high-tension glaucoma, *i.e.*, they exhibit an intraocular pressure (IOP) greater than the normal IOP of about 22 mm Hg. The increased IOP is caused in part by an alteration of the trabecular meshwork (TM), which leads to an obstruction of the normal ability of aqueous humor to leave its chamber surrounding the iris. Elevated IOP can result in progressive visual loss and blindness if not treated appropriately and in a timely fashion.

Because increased IOP is a readily measurable characteristic of glaucoma, the diagnosis of the disease is largely screened for by measuring intraocular pressure (tonometry). Strong, *Ophthalm. Physiol. Opt.* 12:3-7 (1992); Greve *et al.*, *Can. J. Ophthalmol.* 28:201-206 (1993). Unfortunately, because glaucomatous and normal pressure ranges overlap, such methods are of limited value unless multiple readings are obtained. Hitchings, *Br. J. Ophthalmol.* 77:326 (1993); Tuck *et al.*, *Ophthalm. Physiol. Opt.* 13:227-232 (1993); Vaughan *et al.*, In: *General Ophthalmology*, Appleton & Lange, Norwalk, CT, pp. 213-230 (1992); Vernon, *Eye* 7:134-137 (1993). Patients may also have a differential sensitivity to optic nerve damage at a given IOP. For these reasons, additional methods, such as direct examination of the optic disk and determination of the extent of a patient's visual field loss are often conducted to improve the accuracy of diagnosis. Greve *et al.*, *Can. J. Ophthalmol.* 28:201-206 (1993). Moreover, these techniques are of limited prognostic value.

Approximately one-third to one-half of patients with POAG consistently have IOP within the statistically normal range of less than 22 mmHg, however. Tielsch *et al.*, *JAMA* 266:269 (1991); Hitchings, *Br. J. Ophthalmol.* 76:494 (1992); Grosskreutz and Netland, *Int. Ophthalmol. Clin.* 34:173 (1994). These patients have been considered to

have normal-tension glaucoma (NTG) (also known as low-tension glaucoma (LTG)) and exhibit typical glaucomatous cupping of the optic nerve head and visual field loss.

Hitchings and Anderton, *Br. J. Ophthalmol.* 67:818 (1983). See also Werner, *Normal-Tension Glaucoma*, in Rich et al., eds. *The Glaucomas* (2nd ed. 1996): 769-797. NTG has

5 been associated with a disproportionately large amount of cupping, larger than average optic disks, and higher incidences of acquired pit of the optic nerve and optic disk hemorrhage, as compared to high-tension glaucoma patients. *Id.* at page 774. Because IOP is not elevated in NTG, tonometric techniques are of limited diagnostic and prognostic value, and the disease is often difficult to diagnose until the visual field is
10 significantly impaired.

The present invention relates to a gene known as “optineurin” (for optic neuropathy inducing protein), which is also known variously as: tumor necrosis factor-alpha (TNF-alpha) inducible protein (Li *et al.*, *Mol. Cell. Biol.* 18:1601 (1998)); FIP-2 (for adenovirus E3-15.7K interacting protein 2); Huntingtin interacting protein L (Faber
15 *et al.*, *Hum. Mol. Genet.* 7:1463 (1998)), NEMO-related protein (Schwamborn *et al.*, *J. Biol. Chem.* 275:22780 (2000)); transcription factor IIIA (TFIIIA) interacting protein (Moreland *et al.*, *Nucleic Acids Res.* 28:1986 (2000)); and RAB8-interacting protein (Hattula and Peranen, *Curr. Bio.* 10:1603 (2000)).

Optineurin has been reported as being associated with adult-onset POAG, and
20 mutations in the coding region have been reported as correlated with adult-onset NTG/POAG and an increased risk of glaucoma. Rezaie *et al.*, “Adult-Onset Primary Open Angle Glaucoma Caused by Mutations in OPTN”, *Science* 295:1077-1079 (2002). Direct interaction of optineurin with E3-14.7K protein has been reported and it has also

been reported that such interaction utilizes TNF-alpha or FAS-Ligand pathways to mediate apoptosis, inflammation or vasoconstriction. Li *et al.*, *Mol. Cell. Biol.* 18:1601 (1998); Wold, *J. Cell. Biochem.* 53:329 (1993). Optineurin also is reported to function through interactions with other proteins in cellular morphogenesis and membrane trafficking (RAB 8), vesicle trafficking (Huntingtin), transcription activation (TFIIIA), and assembly or activation of two kinases. Li *et al.*, *Mol. Cell. Biol.* 18:1601 (1998); Hattula and Peranen, *Curr. Bio.* 10:1603 (2000); Moritz *et al.*, *Mol. Biol. Cell* 12:2341 (2001); Moreland *et al.*, *Nucleic Acids Res.* 28:1986 (2000); Schwamborn *et al.*, *J. Biol. Chem.* 275:22780 (2000).

SUMMARY OF THE INVENTION

The present invention includes and provides an isolated nucleic acid molecule that comprises at least 20 consecutive nucleotides but not more than 1500 consecutive nucleotides of the sequence of SEQ ID NO: 1. The present invention also includes and provides an isolated nucleic acid molecule comprising a promoter which comprises at least 20 consecutive nucleotides but not more than 1500 consecutive nucleotides of the sequence of SEQ ID NO: 1, the promoter being operably linked to a heterologous nucleic acid sequence. Such heterologous nucleic acid sequences may include, without limitation, coding sequences, toxins, and reporter genes, and also may be capable of being transcribed as an antisense RNA.

The present invention includes a nucleic acid molecule capable of detecting a single nucleotide polymorphism selected from table 1 and a nucleic acid molecule capable of detecting a single nucleotide polymorphism in an optineurin promoter by

specifically detecting said single nucleotide polymorphism in the optineurin promoter,
where the nucleic acid molecule does not specifically hybridize to a nucleic acid molecule
consisting of SEQ ID NO: 1.

Host cells comprising such nucleic acid molecules are also provided by the
5 present invention, including, without limitation, host cells selected from the group
consisting of non-human mammalian cells, bacterial cells, and isolated human cells.

The present invention also provides and includes methods for diagnosing
glaucoma in a sample obtained from a cell or a bodily fluid by detecting a polymorphism
in a promoter region of the optineurin gene, comprising the steps of: (A) incubating under
10 conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, the
marker nucleic acid molecule having a nucleic acid sequence that specifically hybridizes
to a sequence selected from the group consisting of SEQ ID NO: 1 and a complement
thereof, and a complementary nucleic acid molecule obtained from a sample, wherein
nucleic acid hybridization between the marker nucleic acid molecule and the
15 complementary nucleic acid molecule permits the detection of said polymorphism; (B)
permitting hybridization between the marker nucleic acid molecule and the
complementary nucleic acid molecule; and (C) detecting the presence of the
polymorphism, wherein the detection of the polymorphism is diagnostic of glaucoma.

Also provided by the present invention are methods for prognosing glaucoma in a
20 sample obtained from a cell or a bodily fluid by detecting a polymorphism in a promoter
region of the optineurin gene, comprising the steps of: (A) incubating under conditions
permitting nucleic acid hybridization, a marker nucleic acid molecule, the marker nucleic
acid molecule having a nucleic acid sequence that specifically hybridizes to a sequence

selected from the group consisting of SEQ ID NO: 1 and complement thereof, and a complementary nucleic acid molecule obtained from a sample, where nucleic acid hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule permits the detection of the polymorphism; (B) permitting hybridization
5 between the marker nucleic acid molecule and the complementary nucleic acid molecule; and (C) detecting the presence of the polymorphism, where the detection of the polymorphism is prognostic of glaucoma.

Further provided by the present invention are methods for diagnosing or prognosing glaucoma in a sample obtained from a cell or a bodily fluid by detecting a
10 polymorphism in a promoter region of the optineurin gene, comprising the steps of: (A) incubating under conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, the marker nucleic acid molecule having a nucleic acid sequence that specifically hybridizes to a optineurin promoter sequence or its complement, and a complementary nucleic acid molecule obtained from a sample, where nucleic acid
15 hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule permits the detection of the polymorphism; (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule; and (C) detecting the presence of the polymorphism, where the detection of the polymorphism is diagnostic or prognostic of glaucoma.

20 The methods of the present invention may be used to detect a single nucleotide polymorphism, and may further comprise a second marker nucleic acid molecule.

The present invention further provides methods for detecting the presence or absence of a SNP sequence variation in a sample containing DNA, comprising contacting

a labeled nucleic acid capable of detecting a single nucleotide polymorphism selected from table 1 with the DNA of the sample under hybridization conditions and determining the presence of hybrid nucleic acid molecules comprising the labeled nucleic acid.

5 The present invention additionally includes and provides methods for detecting the presence or absence of an optineurin promoter sequence variation, for determining the presence of increased susceptibility to a glaucoma, or to a progressive ocular hypertensive disorder resulting in loss of visual field in a patient, or the severity or progression of glaucoma in a patient, and methods for detecting a polymorphism comprising: obtaining a sample containing human genomic DNA, by providing a nucleic acid molecule capable of
10 detecting a single nucleotide polymorphism located with an optineurin promoter, and detecting the presence or absence of said polymorphism.

Further, the present invention provides kits containing agents of the present invention or kits capable of carrying out a method of the present invention including, without limitation, kits for determining the presence of increased susceptibility to a
15 glaucoma, or to a progressive ocular hypertensive disorder resulting in loss of visual field, or the severity or progression of glaucoma in a patient, comprising a labeled nucleic acid capable of detecting a single nucleotide polymorphism selected from table 1 and a means for detecting hybridization with the labeled nucleic acid, and instructions for using a kit and kits for determining the presence of increased susceptibility to a glaucoma, or to a
20 progressive ocular hypertensive disorder resulting in loss of visual field in a patient, or the severity or progression of glaucoma in a patient, comprising amplification reaction primers that direct amplification of a selected nucleic acid region containing the

characteristic nucleotide substitution of an optineurin promoter SNP sequence variant and an enzyme for amplifying the region containing the characteristic nucleotide substitution.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the genomic structure of optineurin, including regions which
5 interact with other known proteins, putative functional domains, sizes of exons, and position and types of mutations observed.

Figure 2 depicts an interaction of optineurin with other proteins and its potential involvement in alternative pathways of FAS-Ligand (left) and TNF-alpha (right). Interactions are depicted with solid arrows; downstream effects are depicted with open
10 arrows; and a blocking effect of one protein on another is depicted with arrows ending in a circle.

Figure 3 provides a diagrammatic representation of the location of single nucleotide polymorphisms (depicted as an "n" above the polymorphic nucleotide) and DNA motifs (*cis* elements) and putative regulatory regions (depicted by labeled lines
15 beneath the nucleotides of the motif or regulatory region) and repeat elements (depicted by dotted lines above the nucleotides of the repeat element) in the optineurin promoter sequence (SEQ ID NO: 1).

DESCRIPTION OF THE NUCLEIC AND AMINO ACID SEQUENCES

SEQ ID NO: 1 is a *Homo sapiens* nucleotide sequence of optineurin promoter.

20 SEQ ID NO: 2 is a *Homo sapiens* nucleotide sequence of the optineurin promoter and the optineurin coding region.

SEQ ID NOs: 3 through 463 are *Homo sapiens* nucleotide sequences of DNA motifs, repeat elements, and putative regulatory regions identified in the human optineurin promoter.

DEFINITIONS

5 The following definitions are provided as an aid to understanding the detailed description of the present invention.

The abbreviation "EP" refers to patent applications and patents published by the European Patent Office, and the term "WO" refers to patent applications published by the World Intellectual Property Organization. "PNAS" refers to *Proc. Natl. Acad. Sci.*
10 (U.S.A.).

"Amino acid" and "amino acids" refer to all naturally occurring L-amino acids. This definition is meant to include norleucine, norvaline, ornithine, homocysteine, and homoserine.

"Chromosome walking" means a process of extending a genetic map by
15 successive hybridization steps.

The phrases "coding sequence," "structural sequence," and "structural nucleic acid sequence" refer to a physical structure comprising an orderly arrangement of nucleic acids. The coding sequence, structural sequence, and structural nucleic acid sequence may be contained within a larger nucleic acid molecule, vector, or the like. In addition,
20 the orderly arrangement of nucleic acids in these sequences may be depicted in the form of a sequence listing, figure, table, electronic medium, or the like.

A nucleic acid molecule is said to be the “complement” of another nucleic acid molecule if they exhibit complete complementarity, *i.e.*, every nucleotide of one of the molecules is complementary to a nucleotide of the other. Two molecules are “minimally complementary” if they can hybridize to one another with sufficient stability to remain
 5 annealed to one another under at least conventional “low-stringency” conditions.

Similarly, the molecules are “complementary” if they can hybridize to one another with sufficient stability to remain annealed to one another under conventional “high-stringency” conditions. Conventional stringency conditions are described by Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor
 10 Laboratory Press, Cold Spring Harbor, N.Y. (1989); Haymes *et al.*, *Nucleic Acid Hybridization, A Practical Approach*, IRL Press, Washington, DC (1985).

The phrases “DNA sequence,” “nucleic acid sequence,” and “nucleic acid molecule” refer to a physical structure comprising an orderly arrangement of nucleic acids. The DNA sequence or nucleic acid sequence may be contained within a larger
 15 nucleic acid molecule, vector, or the like. In addition, the orderly arrangement of nucleic acids in these sequences may be depicted in the form of a sequence listing, figure, table, electronic medium, or the like. “Nucleic acid” refers to deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

“Exogenous genetic material” is any genetic material, whether naturally occurring
 20 or otherwise, from any source that is capable of being inserted into any organism.

The term “expression” refers to the transcription of a gene to produce the corresponding mRNA and translation of this mRNA to produce the corresponding gene product (*i.e.*, a peptide, polypeptide, or protein). The term “expression of antisense

RNA” refers to the transcription of a DNA to produce a first RNA molecule capable of hybridizing to a second RNA molecule.

As used herein, the term “glaucoma” has its art recognized meaning, and includes primary glaucomas, secondary glaucomas, juvenile glaucomas, congenital glaucomas, and familial glaucomas, including, without limitation, pigmentary glaucoma, high tension glaucoma, low tension glaucoma, normal tension glaucoma, and their related diseases. A disease or condition is said to be related to glaucoma if it possesses or exhibits a symptom of glaucoma, for example, and increased intraocular pressure resulting from aqueous outflow resistance.

“Homology” refers to the level of similarity between two or more nucleic acid or amino acid sequences in terms of percent of positional identity (*i.e.*, sequence similarity or identity).

As used herein, a “homolog protein” molecule or fragment thereof is a counterpart protein molecule or fragment thereof in a second species (*e.g.*, human optineurin is a homolog of mouse optineurin). A homolog can also be generated by molecular evolution or DNA shuffling techniques, so that the molecule retains at least one functional or structure characteristic of the original protein (*see, e.g.*, U.S. Patent No. 5,811,238).

The phrase “heterologous” refers to the relationship between two or more nucleic acid or protein sequences that are derived from different sources. For example, a promoter is heterologous with respect to a coding sequence if such a combination is not normally found in nature. In addition, a particular sequence may be “heterologous” with respect to a cell or organism into which it is inserted (*i.e.* does not naturally occur in that particular cell or organism).

“Hybridization” refers to the ability of a strand of nucleic acid to join with a complementary strand via base pairing. Hybridization occurs when complementary nucleic acid sequences in the two nucleic acid strands contact one another under appropriate conditions.

- 5 “Isolated” refers to a molecule separated from substantially all other molecules normally associated with it in its native state. More preferably an isolated molecule is the predominant species present in a preparation. A isolated molecule may be greater than 60% free, preferably 75% free, more preferably 90% free, and most preferably 95% free from the other molecules (exclusive of solvent) present in the natural mixture. The term
- 10 “isolated” is not intended to encompass molecules present in their native state.

The phrase “operably linked” refers to the functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example, a promoter region may be positioned relative to a nucleic acid sequence such that transcription of a nucleic acid sequence is directed by the promoter region. Thus, a promoter region is “operably

15 linked” to the nucleic acid sequence.

“Polyadenylation signal” or “polyA signal” refers to a nucleic acid sequence located 3’ to a coding region that promotes the addition of adenylate nucleotides to the 3’ end of the mRNA transcribed from the coding region.

- The term “promoter” or “promoter region” refers to a nucleic acid sequence,
- 20 usually found upstream (5’) to a coding sequence, that is capable of directing transcription of a nucleic acid sequence into mRNA. The promoter or promoter region typically provide a recognition site for RNA polymerase and the other factors necessary for proper initiation of transcription. As contemplated herein, a promoter or promoter

region includes variations of promoters derived by inserting or deleting regulatory regions, subjecting the promoter to random or site-directed mutagenesis, *etc.* The activity or strength of a promoter may be measured in terms of the amounts of RNA it produces, or the amount of protein accumulation in a cell or tissue, relative to a promoter whose transcriptional activity has been previously assessed.

The term “protein” “polypeptide” or “peptide molecule” includes any molecule that comprises five or more amino acids. Typically, peptide molecules are shorter than 50 amino acids. It is well known in the art that proteins may undergo modification, including post-translational modifications, such as, but not limited to, disulfide bond formation, glycosylation, phosphorylation, or oligomerization. Thus, as used herein, the term “protein”, “polypeptide” or “peptide molecule” includes any protein that is modified by any biological or non-biological process.

A “protein fragment” is a peptide or polypeptide molecule whose amino acid sequence comprises a subset of the amino acid sequence of that protein. A protein or fragment thereof that comprises one or more additional peptide regions not derived from that protein is a “fusion” protein.

“Recombinant vector” refers to any agent such as a plasmid, cosmid, virus, autonomously replicating sequence, phage, or linear single-stranded, circular single-stranded, linear double-stranded, or circular double-stranded DNA or RNA nucleotide sequence. The recombinant vector may be derived from any source and is capable of genomic integration or autonomous replication.

“Regulatory sequence” refers to a nucleotide sequence located upstream (5’), within, or downstream (3’) to a coding sequence. Transcription and expression of the

coding sequence is typically impacted by the presence or absence of the regulatory sequence.

An antibody or peptide is said to “specifically bind” to a protein, polypeptide, or peptide molecule of the invention if such binding is not competitively inhibited by the presence of non-related molecules.

“Substantially homologous” refers to two sequences which are at least 90% identical in sequence, as measured by the BestFit program described herein (Version 10; Genetics Computer Group, Inc., University of Wisconsin Biotechnology Center, Madison, WI), using default parameters.

“Transcription” refers to the process of producing an RNA copy from a DNA template.

“Transfection” refers to the introduction of exogenous DNA into a recipient host.

“Transformation” refers a process by which the genetic material carried by a recipient host is altered by stable incorporation of exogenous DNA. The term “host” refers to cells or organisms.

“Transgenic” refers to organisms into which exogenous nucleic acid sequences are integrated.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (1995); Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2d ed.), Cold Spring

Harbor Press, Cold Spring Harbor, New York (1989); Birren *et al.*, *Genome Analysis: A Laboratory Manual*, volumes 1 through 4, Cold Spring Harbor Press, Cold Spring Harbor, New York (1997-1999); Coligan *et al.*, *Current Protocols in Immunology*, John Wiley & Sons, N.Y.; Enna *et al.*, *Current Protocols in Pharmacology*, John Wiley & Sons, N.Y.; Fingl *et al.*, *The Pharmacological Basis of Therapeutics* (1975), *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 18th edition (1990); and Albert and Jakobiec, *Principles and Practice of Ophthalmology*, W.B. Saunders Company (1994). These texts can, of course, also be referred to in making or using an aspect of the invention.

10 A. Human optineurin

 In the present invention, a human optineurin promoter has been identified. The transcription start site of the optineurin coding sequence was determined, and a 5 kb fragment of genomic sequence upstream of it was cloned. This fragment was found to contain a promoter responsible for the transcription of optineurin (SEQ ID NO: 1).

15 The present invention provides a number of agents, for example, nucleic acid molecules comprising the optineurin promoter, and nucleic acid molecules comprising key regulatory regions of the optineurin promoter, and provides uses of such agents. The agents of the invention will preferably be "biologically active" with respect to either a structural attribute, such as the capacity of a nucleic acid to hybridize to another nucleic
20 acid molecule, or the ability of a protein to be bound by an antibody (or to compete with another molecule for such binding). Alternatively, such an attribute may be catalytic and

thus involve the capacity of the agent to mediate a chemical reaction or response. The agents will preferably be isolated. The agents of the invention may also be recombinant.

It is understood that any of the agents of the invention can be isolated and/or be biologically active and/or recombinant. It is also understood that the agents of the

5 invention may be labeled with reagents that facilitate detection of the agent, *e.g.*, fluorescent labels, chemical labels, modified bases, and the like. The agents may be used as diagnostic or therapeutic compositions useful in the detection, prevention, and treatment of glaucoma.

In one aspect, the invention relates to nucleic acids comprising non-coding
10 regions or promoter regions associated with the optineurin gene of mammals. These nucleic acids can be used in identifying polymorphisms in the genomes of mammals and humans that predict a susceptibility to glaucomas or diseases related to alterations in IOP. A number of diagnostic or prognostic methods and kits can be designed from these nucleic acids including, without limitation those set forth herein.

15 In one embodiment, the nucleic acids can be used to identify or detect a single base polymorphism in a genome. In other embodiments, two or more single base polymorphisms or multiple base polymorphisms can be identified or detected. The detection of a known polymorphism can be the basis for diagnostic and prognostic methods and kits of the invention. Various methods of detecting nucleic acids can be
20 used in these methods and with the kits, including, but not limited to, solution hybridization, hybridization to microarrays containing immobilized nucleic acids or other immobilized nucleic acids, amplification-based methods such as PCR and the like, and an

appropriate biosensor apparatus comprising a nucleic acid or nucleic acid binding reagent.

In another aspect, the invention relates to specific sequences and variants or mutants from the promoter or 5' regulatory region of the human optineurin gene and nucleic acids incorporating these sequences, variants or mutants. The nucleic acids can be incorporated into the methods and kits of the invention, or used in expression systems, vectors, and cells to produce a protein or polypeptide of interest, or used in methods to identify or detect regulatory proteins or proteins that specifically bind to promoter or regulatory regions of the optineurin gene.

In one embodiment of this aspect of the invention, for example, nucleic acids have an optineurin promoter SNP sequence variant, represented by characteristic nucleotides, as shown in Table 1 below. A nucleic acid incorporating such a characteristic nucleotide can be used to identify and determine individuals at risk for developing glaucoma or a progression from an ocular hypertensive state, and may be associated with therapeutic responsiveness. For example, a SNP in the MYOC gene promoter has been reported to modify therapeutic response and be correlated with resistance to treatment. Colomb *et al.*, *Clin. Genet.* 60:220-225 (2001). The identification of changes in IOP can be done by any known means, however, the "Armaly" criteria is preferred (*see* Armaly, *Arch. Ophthalmol.* 70:492 (1963); Armaly, *Arch. Ophthalmol.* 75:32-35 (1966); Kitazawa *et al.*, *Arch. Ophthalmol.* 99:819-823 (1981); Lewis *et al.*, *Amer. J. Ophthalmol.* 106:607-612 (1988); Becker *et al.*, *Amer. J. Ophthalmol.* 57:543 (1967)).

Table 1: Single Nucleotide Polymorphisms (SNPs) in the Optineurin Promoter

Location in SEQ ID NO: 1	Characteristic Nucleotides
391	a / g
691	a / g
709	a / g
887	t / a
894	a / t
987	a / c
1112	t / c
1505	c / cc
1606	g / a
2405	g / t
2606	a / g
3313	g / a
3555	t / tt
3625	a / g
3629	c / t
3882	t / tt
3988	c / t
4452	g / a

Sequence comparisons of the optineurin promoter region identify a number of

5 DNA motifs (*cis* elements) and regulatory regions, which are listed below in Table 2.

Selected motifs, regulatory regions, and SNPs are shown in Figure 3. Table 2 contains

data obtained by analyzing the optineurin promoter sequence (SEQ ID NO: 1) with

MatInspector, which is a software tool that locates transcription factor binding sites in

DNA sequences (Quandt *et al.*, *Nucleic Acid Research* 23: 4878 (1995)). MatInspector

10 itself, and a full description of the terminology used in Table 2 (*e.g.*, family, matrix, core

similarity, matrix similarity) may be obtained from Genomatix Software GmbH

(München, Germany or www.genomatix.de).

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
OCTB/TST1.01	POU-factor Tst-1/Oct-6	10-24	(-)	1.000	0.877	cagcAAATTccacttc	3
APIF/TCF11/MAFG.01	TCF11/MafG heterodimers, binding to subclass of AP1 sites	14-35	(-)	1.000	0.936	atgataTGACccagcaattcca	4
GATA/GATA.01	GATA binding site (consensus)	24-34	(-)	0.868	0.944	tGATATgaccc	5
EV11/EV11.05	ectopic viral integration site 1 encoded factor	29-39	(-)	1.000	0.830	agttatGATAt	6
FKHD/FREAC2.01	Fork head RElated Activator-2	39-54	(-)	1.000	0.891	gaaagtTAAAcagaga	7
IRFF/IRF1.01	interferon regulatory factor 1	43-55	(-)	0.765	0.852	ggaaagtTAAACA	8
MYT1/MYT1.02	MyT1 zinc finger transcription factor involved in primary neurogenesis	45-55	(-)	1.000	0.881	ggaAAGTtaaa	9
XBBF/MIF1.01	MIBP-1 / RFX1 complex	47-64	(-)	0.850	0.768	gagttccttgGAAAgtta	10
NFAT/NFAT.01	Nuclear factor of activated T-cells	48-59	(-)	1.000	0.951	ccttgGAAAgtt	11
IKRS/IK3.01	Ikaros 3, potential regulator of lymphocyte differentiation	66-78	(+)	1.000	0.847	tcctcGGAAtatt	12
OCTP/OCT1P.01	octamer-binding factor 1, POU- specific domain	67-81	(-)	0.980	0.895	ccaaatATTcCgagg	13
PCAT/CAAT.01	cellular and viral CCAAT box	79-90	(+)	0.847	0.904	tggaaCCAGtga	14
APIF/AP1.01	AP1 binding site	95-103	(-)	0.917	0.955	tTGATTcAg	15
BARB/BARBIE.01	barbiturate-inducible element	103-117	(+)	1.000	0.873	aactAAAgtcgagac	16
PERO/PPARA.01	PPAR/RXR heterodimers	106-125	(+)	1.000	0.713	taaagctgagacAAAGtcca	17
APIF/NFE2.01	NF-E2 p45	109-119	(-)	1.000	0.865	ttgtcTCAGct	18
HNF4/HNF4.01	Hepatic nuclear factor 4	113-126	(+)	1.000	0.861	gagaCAAAAgtcacg	19
SMAD/SMAD3.01	Smad 3 transcription factor involved in TGF-beta signaling	121-128	(-)	1.000	0.996	GTCTggac	20
RORA/RORA1.01	RAR-related orphan receptor alpha1	125-137	(+)	1.000	0.945	agaccaaGGTCaa	21
SF1F/SF1.01	SF1 steroidogenic factor 1	128-136	(+)	1.000	0.988	ccAAGGtca	22
AP4R/TAL1ALPHA47.01	Tal-1alpha/E47 heterodimer	141-156	(+)	1.000	0.888	tagggCAGAtgattca	23
APIF/API.01	AP1 binding site	149-157	(-)	0.934	0.960	aTGAATCAat	24
PIT1/PIT1.01	Pit1, GHF-1 pituitary specific pou domain transcription factor	152-161	(+)	0.871	0.872	attcATGCag	25

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
MINI/MUSCLE INI.03	Muscle Initiator Sequence	157-177	(+)	0.862	0.887	tgacgacCACaccagtgc	26
HAML/AML1.01	run-factor AML-1	164-169	(-)	1.000	1.000	tgTGT	27
OAZF/ROAZ.01	Rat C2H2 Zn finger protein involved in olfactory neuronal differentiation	195-210	(-)	0.750	0.813	ctgCAGCaagggtgt	28
MZF1/MZF1.01	MZF1	214-221	(-)	1.000	0.971	gtGGGGa	29
ETSF/ETS1.01	c-Ets-1 binding site	232-246	(+)	1.000	0.928	ccaGGAActgtttc	30
RPOA/DTYPEPA.01	PolyA signal of D-type LTRs	242-251	(-)	1.000	0.834	tCCATgaac	31
STAT/STAT.01	signal transducers and activators of transcription	244-252	(+)	1.000	0.912	tteatGGAA	32
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	251-262	(-)	0.750	0.756	aaAAATtgttt	33
NFAT/NFAT.01	Nuclear factor of activated T-cells	257-268	(-)	1.000	0.978	ccatgGAAaAat	34
SRFF/SRF.03	serum responsive factor	259-273	(-)	0.819	0.842	aCCATCcatgaaaa	35
CLOX/CDPCR3HD.01	cut-like homeodomain protein	264-273	(+)	0.929	0.936	catgGATGgt	36
MINI/MUSCLE INI.03	Muscle Initiator Sequence	270-290	(-)	1.000	0.862	ccacccccCACcaccacca	37
RREB/RREB1.01	Ras-responsive element binding protein1	271-284	(-)	1.000	0.813	cCCCAcccaccacc	38
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	274-286	(+)	0.819	0.890	gggtGGTGggggg	39
EGRF/WT1.01	Wilms Tumor Suppressor	277-289	(+)	1.000	0.937	gggTGGGgggggtg	40
RREB/RREB1.01	Ras-responsive element binding protein1	285-298	(-)	1.000	0.851	tCCCAaaaccacc	41
SEF1/SEF1.01	SEF1 binding site	310-328	(-)	0.809	0.686	tgctgatgaTCTGagggtg	42
PAX6/PAX6.01	Pax-6 paired domain protein	317-337	(+)	0.754	0.752	gatcatcAGGCattaggtct	43
PDX1/PDX1.01	Pdx1 (IDX1/IPFI) pancreatic and intestinal homeodomain TF	322-340	(-)	1.000	0.784	atgagactcTAATgcctga	44
AHRR/AHRARNT.01	aryl hydrocarbon receptor / Arnt heterodimers	344-359	(-)	1.000	0.937	tctagggtCGTGctt	45
FKHD/XFD3.01	Xenopus fork head domain factor 3	370-383	(-)	1.000	0.852	attgtcAACAgaac	46
SORY/SOX9.01	SOX (SRY-related HMG box)	374-387	(+)	1.000	0.906	tgttgaCAATagggtg	47

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
CREB/TAXCREB.01	Tax/CREB complex	383-397	(+)	0.784	0.838	taggtTCACgctcc	48
PAX6/PAX6.01	Pax-6 paired domain protein	384-404	(+)	1.000	0.766	agggttcACGCtcctatgaaa	49
E2FF/E2F.03	E2F, involved in cell cycle regulation, interacts with Rb p107 protein	384-396	(-)	0.774	0.773	gagCGTgaacct	50
AHRR/AHRARNT.01	aryl hydrocarbon receptor / Arnt heterodimers	387-402	(-)	1.000	0.900	tcataggagCGTgaac	51
OCT1/OCT1.05	octamer-binding factor 1	402-415	(-)	0.888	0.903	ctgcatagATTt	52
AP4R/AP4.03	activator protein 4	408-425	(+)	1.000	0.831	taagCAGCtgcgatct	53
MYOD/MYF5.01	Myf5 myogenic bHLH protein	410-421	(+)	1.000	0.948	atgCAGCtgcg	54
SPIE/GC.01	GC box elements	429-442	(+)	1.000	0.903	aagaGGCGgagctt	55
EGRF/WT1.01	Wilms Tumor Suppressor	452-464	(-)	1.000	0.892	gggTGGGtgagca	56
VMYB/VMYB.02	v-Myb	462-470	(-)	1.000	0.951	agCAACGgg	57
PERO/PPARA.01	PPAR/RXR heterodimers	494-513	(+)	0.807	0.695	tcctgagagggcACAGgcca	58
HNF4/HNF4.01	Hepatic nuclear factor 4	501-514	(+)	0.750	0.848	aggcCACAgggcag	59
B2TF/E2.01	BPV bovine papilloma virus regulator E2	522-537	(-)	0.852	0.878	aaacccgggTGGTga	60
RREB/RREB1.01	Ras-responsive element binding protein1	528-541	(-)	1.000	0.827	cCCCAaaccocggg	61
GKLF/GKLF.01	gut-enriched Krueppel-like factor	543-556	(-)	0.950	0.916	caataaagcaGGG	62
CLOX/CDP.01	cut-like homeodomain protein	546-557	(-)	1.000	0.780	ccAATAaagcag	63
RPOA/LPOLYA.01	Lentiviral Poly A signal	549-556	(-)	1.000	1.000	cAATAAAG	64
HOXF/HOX1-3.01	Hox-1.3, vertebrate homeobox protein	550-579	(+)	1.000	0.748	tttatggacataATTattaggtgtgttc	65
ECAT/NFY.02	nuclear factor Y (Y-box binding factor)	550-560	(-)	1.000	0.914	tgtCCAAtaaa	66
PCAT/CAAT.01	cellular and viral CCAAT box	551-562	(-)	1.000	0.916	tatgtCCAAtaa	67
HMYO/S8.01	S8	555-570	(+)	1.000	0.970	tggacataATTattag	68
NKXH/NKX25.02	homeo domain factor Nkx-2.5/Csx, tinman homolog low affinity sites	559-566	(+)	0.944	0.950	cATAAtta	69
GREF/PRE.01	Progesterone receptor	560-586	(+)	1.000	0.881	atattattaggtgtGTTctttttgg	70
MEF2/MEF2.01	myogenic enhancer factor 2	573-588	(-)	0.750	0.742	cacCAAAaagaacag	71
EBOX/USF.02	upstream stimulating factor	618-625	(+)	0.875	0.938	cCACATgc	72

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
CDXF/CDX2.01	Cdx-2 mammalian caudal related intestinal transcr. factor	620-638	(-)	1.000	0.900	ggatgaatTTTATggcatgt	73
MEF2/AMEF2.01	myocyte enhancer factor	623-640	(+)	1.000	0.817	tgccaTAAAAattcacccc	74
RPOA/DTYPEPA.01	PolyA signal of D-type LTRs	624-633	(+)	1.000	0.816	gCCATaaat	75
TBPF/TATA.02	Mammalian C-type LTR TATA box	624-633	(+)	0.925	0.941	gcCATAAAAAat	76
EBOX/SREBP1.02	sterol regulatory element-binding protein 1	632-642	(+)	1.000	0.832	atTCA Ccccat	77
PIT1/PIT1.01	Pit1, GHF-1 pituitary specific pou domain transcription factor	649-658	(-)	0.820	0.905	aatcATACat	78
APIF/API1.01	API binding site	653-661	(-)	0.934	0.960	aTGAATCAat	79
HMYO/S8.01	S8	662-677	(+)	1.000	0.969	ggctttcaATTacact	80
OCTB/TST1.01	POU-factor Tst-1/Oct-6	665-679	(+)	1.000	0.902	tttcAAATTacactta	81
NKXH/NKX3.01	prostate-specific homeodomain protein NKX3.1	670-682	(-)	1.000	0.892	ttttAAGTgtaat	82
TBPF/ATATA.01	Avian C-type LTR TATA box	675-684	(-)	0.812	0.833	cTTTTTAAgt	83
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	679-689	(+)	1.000	0.899	aaaAAGTtgta	84
CDXF/CDX2.01	Cdx-2 mammalian caudal related intestinal transcr. factor	680-698	(-)	1.000	0.835	tgatggTTTAcactttt	85
HOXF/HOX1-3.01	Hox-1.3, vertebrate homeobox protein	685-714	(+)	1.000	0.773	ttgtaaaaccatcATTAcacttcaattta	86
PDX1/PDX1.01	Pdx1 (IDX1/IPF1) pancreatic and intestinal homeodomain TF	687-705	(+)	0.782	0.805	gtaaaaccaTCA Tacaat	87
SORY/SOX5.01	Sox-5	698-705	(+)	1.000	0.862	attaCAA Ttc	88
RPOA/APOLYA.01	Avian C-type LTR PolyA signal	702-716	(-)	0.853	0.713	ACTAAAatttgaattg	89
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	703-714	(-)	0.750	0.756	taAATTtgaatt	90
OCT1/OCT1.02	octamer-binding factor 1	718-727	(-)	0.755	0.864	gATGGaaata	91
RREB/RREB1.01	Ras-responsive element binding protein 1	731-744	(+)	1.000	0.898	cCCCAaaaatcccc	92
MZF1/MZF1.01	MZF1	740-747	(-)	1.000	0.975	cgaGGGCa	93

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
PCAT/ACAAAT.01	Avian C-type LTR CCAAT box	771-779	(+)	0.825	0.879	ccCCCAAtt	94
STAT/STAT3.01	signal transducer and activator of transcription 3	773-793	(+)	0.750	0.735	cccaatTTCaggaactacig	95
GF11/GF11.01	growth factor independence 1 zinc finger protein acts as transcriptional repressor	786-809	(-)	1.000	0.938	aagacagaAATCagaccagtagtt	96
1RFF/ISRE.01	interferon-stimulated response element	814-828	(-)	1.000	0.825	cagaaaagGAAAGta	97
NFAT/NFAT.01	Nuclear factor of activated T-cells	814-825	(-)	1.000	0.953	aaaagGAAAGta	98
SRFF/SRF.02	serum response factor	818-831	(-)	0.847	0.895	gtCCA Gaaaggaa	99
RPOA/DTYPEPA.01	PolyA signal of D-type LTRs	832-841	(-)	0.750	0.797	tACATtaaat	100
OCTP/OCTP.01	octamer-binding factor 1, POU-specific domain	834-848	(-)	0.849	0.863	ctccataTACattaa	101
XSEC/STAF.01	Se-Cys tRNA gene transcription activating factor	862-883	(-)	0.778	0.765	gctaCCCCagatgccaaagact	102
LYMF/TH1E47.01	Thing1/E47 heterodimer, TH1 bHLH member specific expression in a variety of embryonic tissues	866-881	(+)	1.000	0.914	tttggcatCTGGggtg	103
HOXF/HOX1-3.01	Hox-1.3, vertebrate homeobox protein	881-910	(+)	1.000	0.783	agcaagtacgaatATTAgctaccactca	104
OCTP/OCTP.01	octamer-binding factor 1, POU-specific domain	885-899	(-)	0.980	0.909	actaatATTCgtact	105
SEF1/SEF1.01	SEF1 binding site	904-922	(-)	0.809	0.684	tttatgtgcaTCTGAggtg	106
CDXF/CDX2.01	Cdx-2 mammalian caudal related intestinal transcr. factor	911-929	(-)	1.000	0.863	taataattTTTAgtgcatc	107
OCT1/OCT1.05	Octamer-binding factor 1	915-928	(-)	1.000	0.891	aatatttttATGTg	108
OCT1/OCT1.05	Octamer-binding factor 1	922-935	(+)	0.944	0.894	aaataatcacATAIc	109
CREB/E4BP4.01	E4P4, bZIP domain, transcriptional repressor	925-936	(-)	1.000	0.878	agatatGTAAAta	110
GATA/GATA.01	GATA binding site (consensus)	926-936	(-)	0.868	0.942	agatatGTAAAtaat	111
VBPF/VBP.01	PAR-type chicken vitellogenin promotor-binding protein	926-935	(+)	1.000	0.889	aTTACatc	112

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
EV11/EV11.03	ectopic viral integration site 1 encoded factor	932-946	(-)	0.800	0.927	aGAAAagaagaata	113
NFAT/NFAT.01	Nuclear factor of activated T-cells	944-955	(-)	1.000	0.951	ggaagGAAAaga	114
ETSF/ETS1.01	c-Ets-1 binding site	981-995	(-)	1.000	0.909	gaaGGAAGtagagag	115
YY1F/YY1.01	Yin and Yang 1	1084-1103	(+)	1.000	0.871	gtggcaCCA Tcttggtcag	116
MYOF/NF1.01	nuclear factor 1	1093-1110	(+)	1.000	0.940	tctTGGCtcagcgcaacc	117
XBBF/RFX1.01	X-box binding protein RFX1	1095-1111	(+)	1.000	0.880	tggctcagcGCAAcct	118
APIF/NFE2.01	NF-E2 p45	1095-1105	(+)	1.000	0.865	tggcTCAGcg	119
BRAC/BRACH.01	Brachyury	1145-1168	(+)	0.750	0.693	agcctccaagtAGCTgagattac	120
TTTF/TF1.01	Thyroid transcription factor-1 (TTF1) binding site	1147-1160	(+)	1.000	0.942	cctctCAAGtagct	121
APIF/BEL1.01	Bel-1 similar region	1153-1180	(-)	0.919	0.810	tgggtgcgtgcctgtaatCTCAGctactt	122
GATA/GATA3.01	GATA binding factor 3	1160-1169	(+)	0.824	0.906	tgaGATTaca	123
AHRR/AHRARNT.01	aryl hydrocarbon receptor / Arnt heterodimers	1169-1184	(-)	1.000	0.937	gtagtggtCGTGcct	124
MEF2/HMEF2.01	myocyte enhancer factor	1189-1204	(-)	1.000	0.762	ataataAAATtagcca	125
HNF1/HNF1.02	Hepatic nuclear factor 1	1190-1206	(+)	0.859	0.755	gGCTAatttttatatt	126
TBPF/TATA.01	cellular and viral TATA box elements	1190-1204	(-)	1.000	0.951	ataTAAAaattagcc	127
FKHD/XFD2.01	Xenopus fork head domain factor 2	1192-1205	(-)	1.000	0.905	aataTAAaattag	128
OCT1/OCT1.05	octamer-binding factor 1	1192-1205	(+)	0.944	0.917	ctaatttttATATt	129
MEF2/RSRFC4.02	related to serum response factor, C4	1197-1213	(-)	1.000	0.885	ctactaaaAATAtaaaa	130
GATA/LMO2COM.02	complex of Lmo2 bound to Tal-1, E2A proteins; and GATA-1, half-site 2	1213-1221	(+)	1.000	0.992	gaGATAggg	131
AREB/AREB6.04	AREB6 (Atpal regulatory element binding factor 6)	1219-1227	(+)	1.000	0.970	ggGTTTcac	132
CREB/HLF.01	hepatic leukemia factor	1221-1230	(+)	0.770	0.832	GTTTcaccat	133
ARPI/ARP1.01	apolipoprotein AI regulatory protein 1	1248-1263	(+)	0.826	0.842	tgaactCCTGacctca	134
T3RH/T3R.01	vErbA, viral homolog of thyroid hormone receptor alpha1	1251-1266	(-)	1.000	0.924	gtttgaggtaggagt	135

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
RARF/RAR.01	Retinoic acid receptor, member of nuclear receptors	1252-1261	(-)	0.897	0.961	aggTCAGgag	136
RORA/RORA.01	RAR-related orphan receptor alpha1	1255-1267	(-)	1.000	0.933	cgttgaGGTCag	137
CREB/CREBP1CJUN.01	CRE-binding protein 1/c-Jun heterodimer	1256-1263	(+)	0.769	0.885	tgACCTca	138
LYMF/LYF1.01	LyF-1, enriched in B and T lymphocytes	1270-1278	(-)	1.000	0.988	tttGGGAgg	139
HOBO/HOGNESS.01	Imperfect Hogness/Goldberg Box	1277-1308	(-)	0.764	0.922	ggcgggtggcgcagccTGTAatcccagcactt	140
IKRS/IK2.01	Ikaros 2, potential regulator of lymphocyte differentiation	1280-1291	(+)	1.000	0.960	tgctGGGAttac	141
CREB/TAXCREB.01	Tax/CREB complex	1291-1305	(-)	0.784	0.806	gggtggcTCACgcctg	142
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	1300-1312	(-)	1.000	0.881	ccagGGCGgtggc	143
FKHD/FREAC2.01	Fork head Related Activator-2	1312-1327	(-)	1.000	0.841	agaagTAAAgagggc	144
TBPF/MTATA.01	Muscle TATA box	1324 - 1340	(+)	1.000	0.855	ttctTAAAcccagttc	145
MEF2/MEF2.05	MEF2	1325 - 1334	(-)	1.000	0.984	gggtTAAAGa	146
XBBF/MIF1.01	MBP-1/RFX1 complex	1345 - 1362	(+)	0.850	0.764	gggggtgtagGAAAccta	147
AREB/AREB6.04	AREB6 (Apical regulatory element binding factor 6)	1353 - 1361	(-)	1.000	0.974	agGTTTcgg	148
E2FF/E2F.02	E2F, involved in cell cycle regulation, interacts with Rb p107 protein	1364 - 1371	(-)	1.000	0.849	gcccGAAA	149
LYMF/TH1E47.01	Thing1/E47 heterodimer, TH1 Bhlh member specific expression in a variety of embryonic tissues	1375 - 1390	(+)	1.000	0.928	actgggtCTGgagag	150
MZF1/MZF1.01	MZF1	1387 - 1394	(+)	1.000	0.986	agaGGGga	151
OCT1/OCT1.02	octamer-binding factor 1	1413 - 1422	(+)	1.000	0.943	cATGCaaac	152
PAX5/PAX9.01	zebrafish PAX9 binding sites	1438 - 1461	(+)	0.933	0.774	ggtaCCCAAtgaagtaagggccat	153
RPOA/DTYPEPA.01	PolyA signal of D-type LTRs	1442 - 1451	(+)	1.000	0.779	cCCATtgaag	154
VBPF/VBP.01	PAR-type chicken vitellogenin promoter-binding protein	1446 - 1455	(-)	1.000	0.862	cTTACttcaa	155

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
CREB/CREBP1.01	cAMP-responsive element binding protein 1	1447 - 1454	(-)	0.766	0.820	ttACTTca	156
RPOA/LPOLYA.01	Lentiviral Poly A signal	1460 - 1467	(-)	1.000	0.963	aaATAAAAt	157
XBBF/REFX1.01	X-box binding protein RFX1	1467 - 1483	(+)	1.000	0.883	tttcagcccaGCAAcac	158
HOXF/HOX1-3.01	Hox-1.3, vertebrate homeobox protein	1487 - 1516	(+)	1.000	0.787	cacigataccctcATTAtcaaatggtctt	159
GATA/GATA1.03	GATA-binding factor 1	1497 - 1509	(-)	1.000	0.943	attGATAatgag	160
IKRS/IK3.01	Ikaro3, potential regulator of lymphocyte differentiation	1516 - 1528	(+)	1.000	0.840	tctagGGAAacagt	161
NFAT/NFAT.01	Nuclear factor of activated T-cells	1534 - 1545	(-)	1.000	0.970	cattgGAAAcag	162
AREB/AREB6.04	AREB6 (Atplal regulatory element binding factor 6)	1534 - 1542	(+)	1.000	0.991	ctGTTTcca	163
ECAT/NFY.02	Nuclear factor Y (Y-box binding factor)	1537 - 1547	(+)	1.000	0.917	tttCCAAAtgac	164
CEBP/CEBP.02	C/EBP binding site	1570 - 1587	(-)	0.769	0.854	ggactttgGGAACctccc	165
NFKB/CREL.01	c-Rel	1570 - 1579	(+)	1.000	0.940	gggaggTTCC	166
IKRS/IK2.01	Ikaro2, potential regulator of lymphocyte differentiation	1573 - 1584	(-)	1.000	0.966	ctttGGGAacct	167
XSEC/STAF.01	Se-Cys tRNA gene transcription activating factor	1574 - 1595	(+)	1.000	0.781	ggttCCCAaagtcacagtaggtg	168
SMAD/SMAD3.01	Smad3 transcription factor involved in TGF-beta signaling	1617 - 1624	(+)	1.000	0.997	GTCTgggt	169
CP2F/CP2.01	CP2	1619 - 1629	(-)	1.000	0.915	gcagcacCCAG	170
PAX6/PAX6.01	Pax-6 paired domain protein	1630 - 1650	(-)	0.773	0.753	aggactcAAGCctcagtcacct	171
ARPI/ARP1.01	Apolipoprotein AI regulatory protein 1	1643 - 1658	(+)	1.000	0.829	tgagtcCTTGatgctc	172
RPAD/PADS.01	Mammalian C-type LTR Poly A downstream element	1661 - 1669	(-)	1.000	0.936	gGTGGTctt	173
ECAT/NFY.01	Nuclear factor Y (Y-box binding factor)	1680 - 1695	(+)	1.000	0.899	tcttcCCAAtctgggg	174
SRFF/SRF.02	Serum response factor	1682 - 1695	(-)	0.847	0.868	ccCCAAttgggag	175
SP1F/SP1.01	Stimulating protein 1 SP1, ubiquitinous zinc finger transcription factor	1691 - 1703	(+)	1.000	0.967	tgggGCGGgggga	176

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
EGRF/EGRI.01	Egr-1/Krox-24/NGFI-A intermediate-early gene product	1694 - 1705	(+)	0.830	0.813	gggaggGGAGt	177
APIF/API.03	Activator protein 1	1699 - 1709	(-)	1.000	0.935	agTGACtcccc	178
CMYB/CMYB.01	c-Myb, important in hematopoiesis, cellular equivalent to avian myo-blastosis virus oncogene v-myb	1714 - 1731	(-)	1.000	0.942	tttcacaacaGTTGgagg	179
VMYB/VMYB.02	v-Myb	1716 - 1724	(+)	0.819	0.895	tccAACTgt	180
CEBP/CEBPB.01	CCAAT/enhancer binding protein beta	1721 - 1734	(+)	0.985	0.942	ctgttgtGAAAgcc	181
MINI/MUSCLE INI.02	Muscle Initiator Sequence	1733 - 1753	(+)	1.000	0.853	cctccaccCCACccagctctg	182
EBOX/SREBP1.02	Sterol regulatory element-binding protein 1	1734 - 1744	(+)	0.750	0.838	ctCCACcccac	183
PAX5/PAX9.01	Zebrafish PAX9 binding sites	1736 - 1759	(-)	0.800	0.862	aagaGCCA gactgggtgggtgg	184
SPIF/GC.01	GC box elements	1736 - 1749	(-)	0.872	0.884	gctgGGTGgggtgg	185
NFKB/CREL.01	c-Rel	1752 - 1761	(+)	1.000	0.909	tggtctTTCC	186
ETSF/GABP.01	GABP: GA binding protein	1753 - 1764	(-)	1.000	0.872	ggaGGAAGagcc	187
SEF1/SEF1.01	SEF1 binding site	1761 - 1779	(+)	0.809	0.777	ctccaggacaTCTGGggtta	188
AP4R/TALIALPHAE47.01	Tal-1alpha/E47 heterodimer	1764 - 1779	(-)	1.000	0.867	tacccCAGAtgtcctg	189
REOA/POLYA.01	Mammalian C-type LTR Poly A signal	1778 - 1795	(-)	0.822	0.823	cAATACAtccatgatcta	190
EVII/EVI1.02	Ectopic viral integration site 1 encoded factor	1814 - 1824	(+)	1.000	0.837	agacAAGAaga	191
CMYB/CMYB.01	c-Myb, important in hematopoiesis, cellular equivalent to avian myo-blastosis virus oncogene v-myb	1836 - 1853	(+)	1.000	0.936	tctaagagctGTTGccag	192
XBBF/RFX1.01	X-box binding protein RFX1	1844 - 1860	(-)	1.000	0.922	tggactctcgGCAAcag	193
MYOF/NF1.01	Nuclear factor 1	1850 - 1867	(-)	1.000	0.959	cgtTGGCtggactctgg	194
EGRF/EGR3.01	Early growth response gene 3 product	1859 - 1870	(-)	1.000	0.795	gaGCGTtggtcg	195
NOLF/OLF1.01	olfactory neuron-specific factor	1879 - 1900	(-)	1.000	0.825	aacgagTCCcttgggcttct	196
AREB/AREB6.04	AREB6 (Atp1a1 regulatory element binding factor 6)	1907 - 1915	(-)	1.000	0.970	ctGTTTgga	197

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
GREF/ARE.01	Androgen receptor binding site	1929 - 1935	(-)	1.000	0.796	gtttgatgttccttgTGTtcccttcc	198
IRFF/IRF2.01	Interferon regulatory factor 2	1929 - 1941	(+)	0.750	0.803	ggaaaggGAACac	199
LDPS/LDSPOLYA.01	Lentiviral Ply A downstream element	1931 - 1946	(-)	0.862	0.923	tccTTGTgtcccttt	200
XBBF/RFX1.02	X-box binding protein RFX1	1933 - 1950	(+)	0.881	0.904	aggaacacaaGGAACat	201
RPOA/DITYPEA.01	Poly A signal of D-type LTRs	1946 - 1955	(+)	0.750	0.777	aACATcaaac	202
IKRS/IK1.01	Ikaros 1, potential regulator of lymphocyte differentiation	977-1989	(-)	1.000	0.918	gtgtGGGAagggtt	203
XSEC/STAF.02	Se-Cys tRNA gene transcription activating factor	979-1999	(+)	1.000	0.864	cctCCCCAcactgctacat	204
RPOA/DITYPEA.01	PolyA signal of D-type LTRs	2006-2015	(+)	0.75	0.777	aCCACaaaac	205
HAML/AML1.01	run-factor AML-1	2006-2011	(-)	1.000	1.000	tgTGGT	206
HAML/AML1.01	run-factor AML-1	2014-2019	(-)	1.000	1.000	tgTGGT	207
ECAT/NFY.03	Nuclear factor Y (Y-box binding factor)	2019-2032	(+)	0.777	0.847	atcaACAAAtcagc	208
TBPF/ATATA.01	Avian C-type LTR TATA BOX	2046-2055	(+)	0.812	0.824	tTATTTCagt	209
IRFF/IRF1.01	interferon regulatory factor 1	2047-2059	(-)	1.000	0.879	aaaaactGAAAta	210
VMYB/VMYB.01	v-Myb	2050-2059	(-)	0.876	0.910	aaaAACTgaa	211
PAX6/PAX6.01	Pax-6 paired domain protein	2053-2073	(+)	0.754	0.751	agtgtttTCGtgcatttaga	212
E2FF/E2F.02	E2F involved in cell cycle regulation, interacts with Rb p107 protein	2056-2063	(-)	0.857	0.866	gcgaAAAA	213
PAX5/PAX9.01	zebrafish PAX9 binding sites	2079-2102	(+)	0.933	0.793	tctaCCCAtggaagtgtcaggaa	214
MTF1/MTF-1.01	Metal transcription factor 1, MRE	2087-2101	(-)	1.000	0.873	tectGCAcactcca	215
ETSF/ETS2.01	c-Ets-2 binding site	2095-2108	(+)	1.000	0.863	tgcaGGAAtgatgga	216
ZFIA/ZID.01	zinc finger with interaction domain	2100-2112	(-)	0.777	0.865	tgACTCcatcttc	217
AP1F/APIFJ.01	activator protein 1	2104-2114	(-)	1.000	0.979	ggTGAAtccat	218
VMYB/VMYB.02	v-Myb	2113-2121	(+)	1.000	0.912	ccaAACGgg	219
ETSF/ELK1.01	Elk-1	2114-2129	(+)	0.866	0.83	caaacGGATgatcca	220
NFKB/NFKAPPAB.02	NF-kappaB	2118-2129	(+)	0.929	0.815	cGGGATgatoca	221
AREB/AREB6.04	AREB6 (Atpla1 Regulatory element binding factor 6)	2134-2142	(-)	1	0.997	ctGTTTctt	222
ZF11A/ZID.01	zinc finger with interaction domain	2146-2158	(+)	1	0.889	cgGCTCtaacaca	223

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO.
XBBF/RFX1.02	X-box binding protein RFX1	2149-2166	(+)	1	0.899	ctctaacaacGCAAcag	224
CMYB/CMYB.01	c-Myb, important in hematopoiesis, cellular equivalent to avian myoblastosis virus oncogene v-myb	2157-2174	(-)	1	0.916	gtttgtgctGTTGcttg	225
CREB/TAXCREB.02	Tax/CREB complex	2205-2219	(-)	0.750	0.741	gaggaaaTACGcttt	226
ETSF/ETS2.01	c-Ets-2 binding site	2208-2121	(-)	1.000	0.907	aagaGGAAtacgt	227
NFAT/NFAT.01	Nuclear factor of activated T-cells	2210-2221	(-)	1.000	0.962	aagagGAAAtac	228
EV11/EV11.02	ectopic viral integration site 1 encoded factor	2222-2232	(-)	1.000	0.854	tgagAAGAtta	229
OAZF/ROAZ.01	Rat C2H2 Zn finger protein involved in olfactory neuronal differentiation	2231-2246	(+)	0.750	0.789	cagCATCcttagtga	230
EBOR/DELTAEF1.01	deltaEF1	2238-2248	(-)	1.000	0.985	cctcACCtaag	231
CREB/CREBP1.01	cAMP-responsive element binding protein 1	2239-2246	(-)	0.766	0.801	tcACCTaa	232
HNF4/HNF4.02	Hepatic nuclear factor 4	2253-2267	(+)	0.750	0.776	tggtccAGAGgct	233
GATA/GATA.01	GATA binding site (consensus)	2262-2272	(-)	1.000	1.000	aGATAAgcct	234
CREB/E4BP4.01	E4BP4, bZIP domain, transcriptional repressor	2265-2276	(+)	0.758	0.840	ccttatCTAAaa	235
TBP/ATATA.01	Avian C-type LTR TATA box	2265-2274	(-)	0.834	0.850	tTAGATAagg	236
XBBF/MIF1.01	MIBP-1/RFX1 complex	2281-2298	(-)	0.800	0.774	acgtgccccGCCAcccc	237
EBOX/USF.02	upstream stimulating factor	2304-2311	(+)	0.875	0.931	aCACATgt	238
VBPF/VBP.01	PAR-type chicken vitellogenin promoter-binding protein	2305-2314	(-)	1.000	0.863	aTTACatgtg	239
IKRS/IK2.01	Ikaros 2, potential regulator of lymphocyte differentiation	2310-2321	(-)	1.000	0.960	tgctGGGAttac	240
NRSF/NRSF.01	neuron-restrictive silencer factor	2315-2335	(+)	1.000	0.685	cccAGCActtggaggccga	241
TANT/TANTIGEN.01	Major T-antigen binding site	2326-2344	(+)	0.759	0.872	ggaaggcCGAGgcaggtgg	242
AREB/AREB6.01	AREB6 (Atp1a1 regulatory element binding factor 6)	2335-2347	(-)	1.000	0.921	gatccACCTgct	243
MYOD/MYOD.02	myoblast determining factor	2336-2345	(-)	1.000	0.992	tcCACctgcc	244
EBOX/SREBP1.02	sterol regulatory element-binding protein 1	2344-2354	(+)	1.000	0.791	gaTCAccgag	245

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
RARF/RAR.01	Retinoic acid receptor, member of nuclear receptors	2353-2362	(+)	0.897	0.961	aggTCAGgag	246
CREB/HLF.01	hepatic leukemia factor	2384-2393	(-)	0.770	0.857	GTTTcgccat	247
CLOX/CDPCR3HD.01	cut-like homeodomain protein	2394-2403	(-)	0.929	0.941	tattGATGag	248
OCT1/OCT1.02	octamer-binding factor	2409-2418	(+)	1.000	0.941	aATGCaaaa	249
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	2414-2425	(+)	0.750	0.775	aaAAAATtagctt	250
HAML/AML1.01	run1-factor AML-1	2428-2433	(+)	1.000	1.000	tgTGGT	251
IKRS/IK2.01	Ikaros 2, potential regulator of lymphocyte differentiation	2445-2456	(-)	1.000	0.967	ggctGGGAtiac	252
AHRR/AHRARNT.02	aryl hydrocarbon / Arnt heterodimers, fixed core	24875-2493	(-)	0.750	0.772	tgggttGAGTgattctcc	253
CHOP/CHOP.01	heterodimers of CHOP and C/EBPalpha	2500-2512	(-)	1.000	0.943	cacTGCAatctcc	254
OCT1/OCT1.01	octamer-binding factor 1	2517-2535	(+)	1.000	0.802	gagatTATGccactgcact	255
MEF2/MEF2.01	myogenic enhancer factor 2	2565-2580	(+)	0.750	0.752	ctcAAAAAataaata	256
CDXF/CDX2.01	Cdx-2 mammalian caudal related intestinal transcr. Factor	2571-2589	(-)	1.000	0.835	caaaggtTTTAttttattt	257
EV11/EV11.03	ectopic viral integration site 1 encoded factor	2571-2581	(+)	0.750	0.788	aaataAAATaa	258
RPOA/POLYA.01	Mammalian C-Type LTR Poly A signal	2576-2593	(+)	1.000	0.806	aAATAAAaccttggggc	259
E2FF/E2F.02	E2F, involved in cell cycle regulation, interacts with Rb p107 protein	2586-2593	(-)	1.000	0.849	gcccCAAA	260
XSEC/STAF.01	Se-Cys tRNA gene transcription activating factor	2606-2627	(-)	1.000	0.812	aatcCCCCAgaattctggactct	261
NFKB/NFKAPPAB.02	NF-kappaB	2621-2632	(+)	0.929	0.877	gGGGATtttcaa	262
HNF1/HNF1.02	Hepatic nuclear factor 1	2635-2651	(+)	0.859	0.778	gGCTAttcaataatgg	263
RPOA/LPOLYA.01	Lentiviral Poly A signal	2642-2649	(+)	1.000	0.971	caATAAAAT	264
TBP/TATA.01	cellular and viral TATA box elements	2646-2660	(-)	1.000	0.925	ataTAAAtcccattt	265

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
HMTB/MTBF.01	muscle-specific Mt binding site	2649-2657	(+)	1.000	0.901	tgggATTa	266
CREB/HLF.01	hepatic leukemia factor	2659-2668	(-)	1.000	0.869	GTTAgtgat	267
VBPF/VBP.01	PAR-type chicken vitellogenin promoter-binding protein	2659-2668	(-)	0.830	0.886	gTTATgtgat	268
CREB/CREB.03	cAMP-responsive element binding protein	2681-2692	(+)	1.000	0.915	tcTGACgcagtt	269
GATA/GATA1.01	GATA binding factor 1	2692-2705	(-)	1.000	0.963	tagtGATAggaga	270
CLOX/CLOX.01	Clox	2700-2714	(-)	1.000	0.823	aaaATCGaatttg	271
NFAT/NFAT.01	Nuclear factor of activated T-cells growth factor independence 1 zinc finger protein acts as transcriptional repressor	2709-2720	(-)	1.000	0.972	tgaagGAAAaatic	272
GF11/GF11.01		2728-2751	(+)	1.000	0.943	aatttaaaAATCacatcaaggat	273
MEF2/MEF2.05	MEF2	2728-2737	(+)	1.000	0.969	aattTAAaaa	274
GATA/GATA3.02	GATA-binding factor 3	2746-2755	(+)	0.812	0.904	agGGATctaa	275
FKHD/FREAC3.01	Fork head Related Activator-3	2747-2762	(+)	0.750	0.849	gggatCTAAataaga	276
MEF2/MEF2.05	MEF2	2749-2758	(+)	1.000	0.960	gacTAAAta	277
RPOA/LPOLYA.01	Lentiviral Poly A signal	2754-2761	(+)	1.000	0.992	aaATAAAg	278
HMTB/MTBF.01	muscle-specific Mt binding site	2766-2774	(-)	1.000	0.911	agctATTa	279
VMYB/VMYB.02	v-Myb	2780-2788	(-)	0.819	0.892	cccAACTga	280
SMAD/SMAD3.01	Smad3 transcription factor involved in TGF beta signaling	2788-2795	(+)	1.000	0.993	GTCTggtc	281
HNF4/HNF4.02	Hepatic nuclear factor 4	2801-2815	(-)	0.750	0.778	aaggaccAAACctct	282
MYT1/MYT1.02	MyT1 zinc finger transcription factor involved in primary neurogenesis	2815-2825	(-)	1.000	0.897	agaAAGTtcta	283
HEAT/HSF1.01	heat shock factor 1	2816-2825	(-)	1.000	0.98	AGAAagtctt	284
MZF1/MZF1.01	MZF1	2847-2854	(-)	1.000	0.978	aatGGGGa	285
TBPF/TATA.02	Mammalian C-Type LTR TATA box	2852-2861	(-)	0.885	0.914	tcTGTAATAAT	286
GATA/GATA1.03	GATA-binding factor 1	2856-2868	(+)	1.000	0.981	tacaGATAaaggg	287
ETSF/PU1.01	Pu. 1 (Pul20) Ets-like transcription factor identified in lymphoid B cells	2868-2883	(+)	1.000	0.870	gaatgaGGAAGggtta	288
CREB/HLF.01	hepatic leukemia factor	2885-2894	(-)	1.000	0.892	GTTActcat	289

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
VBPF/VBP.01	PAR-type chicken vitellogenin promoter-binding protein	2885-2894	(-)	1.000	0.913	gTTACttcat	290
RORA/RORA2.01	RAR-related orphan receptor alpha2	2890-2902	(+)	1.000	0.928	gtaacttGGTCaa	291
LDPS/LDSPOLYA.01	Lentiviral Poly A downstream element	2932-2947	(+)	1.000	0.900	ggagTGTgtgtgcatg	292
EBOX/USF.02	upstream stimulating factor	2943 - 2950	(-)	0.875	0.933	aCACATgc	293
NFKB/NFKAPPAB.01	NF-kappaB (p50)	2966-2975	(-)	1.000	0.885	GGGgtgccc	294
MINI/MUSCLE.INI.03	Muscle Initiator Sequence	2967-2987	(+)	1.000	0.879	ggcacccccCACccgacccc	295
REBV/EBVR.01	Epstein-Barr virus transcription factor R	2967-2987	(-)	1.000	0.828	ggggtcgggggtgggGGTGcc	296
EGRF/WT1.01	Wilms Tumor Suppressor	2968-2980	(-)	1.000	0.909	gggTGGGGgggtgc	297
SPIF/GC.01	GC box elements	2970-2983	(-)	0.872	0.897	tcggGGTGgggggt	298
RREB/RREB1.01	Ras-responsive element binding protein 1	2973-2986	(+)	1.000	0.826	cCCCCaccccgaccc	299
PCAT/ACAAT.01	Avian C-type LTR CCAAT box	2986-2994	(+)	0.793	0.866	ccACCACtg	300
ARPI/ARP1.01	apolipoprotein AI regulatory protein 1	2993-3008	(-)	1.000	0.861	tgattcCTTGctctca	301
MYT1/MYT1.02	MyT1 zinc finger transcription factor involved in primary neurogenesis	3015-3025	(-)	1.000	0.893	tcaAAGTtggt	302
IRFF/ISRE.01	interferon-stimulated response element	3033-3047	(+)	1.000	0.800	ctgtaccaGAAActc	303
EGRF/WT1.01	Wilms Tumor Suppressor	3053-3065	(-)	1.000	0.900	gtgTGGGaggctc	304
RARF/RAR.01	Retinoic acid receptor, member of nuclear receptors	3085-3094	(-)	1.000	0.987	aggTCAccca	305
RORA/RORA1.01	RAR-related orphan receptor alpha1	3088-3100	(-)	1.000	0.956	agaagaaGGTCac	306
EV11/EV11.01	ectopic viral integration site 1 encoded factor	3092-3107	(-)	1.000	0.728	agccAAGAGaagaagg	307
OCT1/OCT1.05	octamer-binding factor 1	3124-3137	(+)	0.888	0.911	ctcattttaATTCa	308
OCTB/TST1.01	POU-factor Tst-1/Oct-6	3125-3139	(-)	1.000	0.961	agtgAAATTaaaatga	309

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO.
RB1T/BRIGHT.01	Bright, B B326cell regulator of IgH transcription	3127-3139	(-)	1.000	0.959	agtgaATTAAaat	310
NKXH/NKX25.02	homeo domain factor Nkx-2.5/Csx, tinman homolog low affinity sites	3129-3136	(+)	1.000	0.874	tTTAAAttc	311
GREF/PRE.01	Progesterone receptor binding site	3140-3166	(+)	1.000	0.847	ttcatagtggtttTGTtctgtttt	312
RPOA/POLYA.01	Mammalian C-type LTR Poly A signal	3142-3159	(-)	0.822	0.711	gAACAAAAcacacatag	313
AHRR/AHR.01	aryl hydrocarbon / dioxin receptor growthfactor independence 1 zinc finger protein acts as transcriptional repressor	3193-3210	(-)	0.750	0.840	actccagctGGGTgaga	314
GFI1/GFI1.01		3213-3236	(+)	1.000	0.953	agtgtgcAATCacagctcattgc	315
LYMF/LYF1.01	LyF-1, enriched in B and T lymphocytes	3277-3285	(-)	1.000	0.988	tttGGGAgg	316
HOB0/HOGNESS.01	Imperfect Hogness/Goldberg Box	3284-3315	(-)	0.764	0.917	cacgggtgcacaccTGTaatccacgactt	317
IKRS/IK2.01	Ikaros 2, potential regulator of lymphocyte differentiation	3287-3298	(+)	1.000	0.960	tgctGGGAttaac	318
MYOD/E47.02	TAL1/E47 dimers	3293-3308	(+)	1.000	0.932	gattaCAGGtGtgagc	319
AREB/AREB6.02	AREB6 (Atpal regulatory element binding factor 6)	3295-3306	(-)	1.000	0.979	tcaCACCCtgtaa	320
BRAC/TBX5.01	T-Box factor 5 site (TBX5), mutations related to Holt-Oram syndrome	3297-3308	(+)	1.000	0.991	acaGGTGragc	321
TBPF/MTATA.01	Muscle TATA box	3323-3339	(-)	1.000	0.888	ctgtrTAAAacccata	322
FKHD/FREAC2.01	Fork head Related Activator-2	3327-3342	(+)	1.000	0.854	gggttrTAAAacagtaa	323
MEF2/MEF2.05	MEF2	3329-3338	(+)	1.000	0.986	gtttTAAAcac	324
CEBP/CEBP.02	C/EBP binding site	3359-3376	(-)	0.957	0.857	tgccctgcgGTAAGtcgta	325
NOLF/OLF1.01	olfactory neuron-specific factor	3383-3404	(-)	1.000	0.822	aaagggtCCcgggggctgt	326
AP2F/AP2.01	activator protein 2	3388-3399	(-)	0.976	0.895	gtCCCCcggggg	327
MZF1/MZF1.01	MZF1	3391-3398	(+)	1.000	0.980	cggGGGGa	328
HEN1/HEN1.01	HEN1	3415-3436	(+)	1.000	0.873	ccagggtacAGCtgtgacaccg	329
AP4R/AP4.01	activator protein 4	3421-3430	(-)	1.000	0.974	caCAGCtgta	330
GATA/GATA1.02	GATA-binding factor 1	3448-3461	(-)	1.000	0.934	actggGATAatcca	331
NFKB/NFKAPPAB.02	NF-kappaB	3448-3459	(-)	0.929	0.822	tGGGATaatcca	332

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
FKHD/HF8.01	HNF-3/Fkh Homolog-8	3461-3473	(+)	1.000	0.970	tagataAAACaaaa	333
GATA/GATA.01	GATA binding site (consensus)	3462-3472	(+)	1.000	0.949	aGTAAAacaaaa	334
SORY/SRY.01	sex-determining region Y gene product	3464-3475	(+)	1.000	0.946	ataaACAAaaat	335
CREB/CREB.02	cAMP-responsive element binding protein	3480-3491	(-)	1.000	0.87	ggaaTGACgcat	336
PAX3/PAX3.01	Pax-3 paired domain protein, expressed in embryogenesis, mutations correlate to Waardenburg Syndrome	3482-3494	(+)	1.000	0.785	TCGTcattccatt	337
TEAF/TEF1.01	TEF-1 related muscle factor	3484-3495	(+)	1.000	0.834	gtCATTccaatt	338
PAX1/PAX1.01	Pax1 paired domain protein, expressed in the developing vertebra 1 column of mouse embryos	3490-3507	(+)	0.750	0.733	CCATttctctgtatat	339
NFAT/NFAT.01	Nuclear factor of activated T-cells	3508-3519	(-)	1.000	0.966	gcttgGAAAAaat	340
BARB/BARBIE.01	barbiturate-inducible element	3514-3528	(-)	1.000	0.885	atgaAAAGggcttgg	341
OCT1/OCT1.02	octamer-binding factor 1	3520-3529	(-)	0.763	0.823	cATGAaaagg	342
APIF/TCF11MAFG.01	TCF11/MafG heterodimers, binding to subclass of AP1 sites	3522-3543	(+)	0.777	0.808	ttttcaTGAAtgatcagttatt	343
PIT1/PIT1.01	Pit1, GHF-1 pituitary specific pou domain transcription factor	3527-3536	(-)	1.000	0.855	gataATTcat	344
VMYB/VMYB.01	v-Myb	3534-3543	(-)	0.876	0.938	aatAACTgat	345
ETSF/ETS2.01	c-Ets-2 binding site	3537-3550	(-)	1.000	0.946	tgcaggAAataact	346
GFI1/GFI1.01	growth factor independence 1 zinc finger protein acts as transcriptional repressor	3541-3564	(-)	1.000	0.977	aaaaaaaaAATCagtcaggaaat	347
APIF/APIFJ.01	activator protein 1	3592-3602	(-)	1.000	0.968	ggTGACagagt	348
EBOX/SREBP1.02	sterol regulatory element-binding protein 1	3617-3627	(-)	0.750	0.791	gaTCATgccac	349

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
PAX3/PAX3.01	Pax-3 paired domain protein, expressed in embryogenesis, mutations correlate to Waardenburg Syndrome	3628-3640	(+)	0.780	0.765	TCGGctcgctgca	350
HEAT/HSF1.01	heat shock factor 1	3663-3672	(-)	1.000	0.937	AGAAgaatcg	351
XSEC/STAF.02	Se-Cys tRNA gene transcription activating factor	3706-3726	(+)	0.810	0.870	gagtACCAatcatgcccgcta	352
P53F/P53.01	tumor suppressor p53	3712-3731	(+)	1.000	0.660	catCATGccccggctaatttt	353
MEF2/RSRFC4.02	related to serum response factor, C4	3729-3745	(-)	1.000	0.885	ctactaaaAATAcaaaa	354
SRFF/SRF.01	serum response factor	3755-3772	(+)	0.773	0.653	ttcaccaTATTggccagg	355
ECAT/NFY.02	nuclear factor Y (Y box binding factor)	3760-3770	(-)	1.000	0.920	tggCCAAatag	356
HNF4/HNF4.02	Hepatic nuclear factor 4	3788-3802	(-)	0.750	0.784	cagatcgCAAGgtcc	357
LYMF/LYF1.01	LyF-1, enriched in B and T lymphocytes	3813-3821	(-)	1.000	0.988	tttGGGAgg	358
HOBO/HOGNESS.01	Imperfect Hogness/Godberg Box	3820-3851	(-)	0.764	0.928	cgcggtggctcaagccTGTAatcccagcactt	359
IKRS/IK2.01	Ikars 2, potential regulator of lymphocyte differentiation	3823-3834	(+)	1.000	0.960	tgctGGGAttac	360
CREB/TAXCREB.01	Tax/CREB complex	3834-3848	(-)	0.784	0.806	ggtggtCACGcctg	361
EBOX/MYCMAX.03	MYC-MAX binding sites	3848-3857	(-)	0.813	0.920	gcCAGGcgcg	362
GATA/GATA3.02	GATA-binding factor 3	3866-3875	(+)	0.875	0.910	acTGAataa	363
EV11/EV11.04	ectopic viral integration site 1	3868-3882	(+)	1.000	0.809	tGATAataaagaat	364
MEF2/MEF2.05	encoded factor	3869-3878	(+)	1.000	0.968	gataTAAaaa	365
TBPF/TATA.01	cellular and viral TATA box elements	3870-3884	(+)	1.000	0.958	ataTAAaagaattt	366
RPOA/APOLYA.01	Avian C-type LTR PolyA signal	3874-3888	(-)	0.829	0.754	AAAAAAaattcttttt	367
MEF2/MEF2.05	MEF2	3884-3893	(-)	1.000	0.969	aattTAAaAa	368
EBOX/SREBP1.02	sterol regulatory element-binding protein 1	3899-3909	(+)	0.750	0.849	trTCTCccac	369
MZF1/MZF1.01	MZF1	3903-3910	(-)	1.000	1.000	agtGGGGa	370
MINI/MUSCLE INI.03	Muscle Initiator Sequence	3904-3924	(+)	1.000	0.881	ccccactccCACcccaggct	371

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
RREB/RREB1.01	Ras-responsive element binding protein 1	3904-3917	(+)	1.000	0.831	cCCCActcccacc	372
EGRF/WT1.01	Wilms Tumor Suppressor	3905-3917	(-)	1.000	0.941	gggTGGGagtgagg	373
AP2F/AP2.01	activator protein 2	3913-3924	(+)	0.976	0.929	caCCCCCagagct	374
TBPF/MTATA.01	Muscle TATA box	3919-3945	(+)	1.000	0.917	ccttaTAAAGcagcctc	375
HAML/AML1.01	Runt-factor AML-1	3968-3973	(+)	1.000	1.000	tgTGGT	376
ETSF/ELK1.02	Elk-1	3983-3996	(+)	1.000	0.926	gggcccGGAAtgg	377
LYMF/THIE47.01	Thing 1/E47 heterodimer, TH1 bHLH member specific expression in a variety of embryonic tissues	3991-4006	(+)	1.000	0.910	aattgggtCTGGggca	378
PAX5/PAX5.01	B-cell-specific activating protein	4016-4043	(-)	0.904	0.862	cccaagAGCAGggcagagaagcaagcaa	379
LTUP/TAACC.01	Lentiviral TATA upstream element	4037-4059	(-)	1.000	0.838	tgcccttgaggCTAACCCcaaga	380
PAX5/PAX5.01	B-cell-specific activating protein	4050-4077	(+)	0.952	0.820	ctcaggGGCAgggttgagagtcaggctt	381
PCAT/CLTR CAAT.01	Mammalian C-type LTR CCAAT box	4056-4080	(-)	0.803	0.758	gcCAAGcctgactctcaacctgcc	382
MYOD/MYF5.01	Myf5 myogenic bHLH protein	4082-4093	(+)	1.000	0.920	aggCAGCagagag	383
ETSF/ELK1.01	Elk-1	4084-4099	(+)	0.800	0.832	gcagcaGGA Ggtccag	384
SMAD/SMAD3.01	Smad3 transcription factor involved in TGF-beta signaling	4094-4101	(-)	1.000	0.996	GTCTggac	385
GATA/GATA2.02	GATA-binding factor 2	4120-4129	(+)	1.000	0.917	ggaGATAAcga	386
HMTB/MTBF.01	Muscle-specific Mt binding site	4121-4129	(-)	0.884	0.912	tggtATCTc	387
EGRF/WT1.01	Wilms Tumor Suppressor	4131-4143	(+)	0.813	0.893	gagAGGgGgcac	388
PERO/PPARA.01	PPAR/RXR heterodimers	4143-4162	(-)	1.000	0.694	ctgaaacaggaaaAAAGgcag	389
GKLF/GKLF.01	gut-enriched Krueppel-like factor	4146-4159	(-)	0.936	0.918	aaacaggaaaAAGG	390
NFAT/NFAT.01	Nuclear factor of activated T-cells	4147-4158	(-)	1.000	0.984	aacagGAAAaag	391
AREB/AREB6.04	AREB6 (Atp1 a1 regulatory element binding factor 6)	4154-4162	(+)	1.000	1.000	ctGTTTcag	392
SORY/SRY.01	sex-determining region Y gene product	4181-4192	(-)	1.000	0.950	aaaaACAAaaca	393
FKHD/HFH2.01	HNF-3/Fkh Homolog 2	4183-4194	(-)	1.000	0.938	aaaaAACAAAA	394
EGRF/WT1.01	Wilms Tumor Suppressor	4210-4222	(-)	0.813	0.871	gagAGGgGaggag	395
EGRF/WT1.01	Wilms Tumor Suppressor	4222-4234	(-)	0.813	0.871	gagAGGgGaggag	396
GKLF/GKLF.01	gut-enriched Krueppel-like factor	4252-4265	(-)	1.000	0.916	agagagagAGGG	397

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	4267-4279	(-)	0.844	0.888	ggagGGAGgggga	398
GKLF/GKLF.01	gut-enriched Krueppel-like factor	4269-4282	(-)	0.950	0.936	gaaggagggaGGG	399
OCT1/OCT1.02	octamer-binding factor1	4321-4330	(+)	1.000	0.849	gATGCacata	400
EVII/EVII.06	ectopic viral integration site 1 encoded factor	4346-4354	(-)	0.750	0.835	acaAGGTag	401
TCFF/TCF11.01	TCF11/KCR-F1/Nrfl homodimers	4353-4365	(+)	1.000	0.991	GTCAtctgtgt	402
MINI/MUSCLE INI.01	Muscle Initiator Sequence	4383-4403	(+)	1.000	0.857	tccctctCCA Caccagcaga	403
NRSF/NRSF.01	neuron-restrictive silencer factor	4412-4432	(+)	1.000	0.746	ttcAGCAacaagaatagccga	404
CLOX/CDPCR3.01	cut-like homeodomain protein	4414-4428	(+)	0.888	0.770	cagcaacaagaATAG	405
PCAT/CLTR CAAT.01	Mammalian C-type LTR CCAAT box	4455-4479	(+)	0.803	0.761	ccCAA Gaagcattctgcaggcttic	406
BARB/BARBIE.01	barbiturate-inducible element	4475-4489	(-)	1.000	0.875	tcaaAAA Gcagaag	407
MEF2/MMEF2.01	myocyte enhancer factor	4489-4504	(-)	1.000	0.892	tgcttTAAAatacact	408
TBPF/TATA.02	Mammalian C-type LTR TATA box	4494-4503	(-)	0.927	0.938	gcTTTAAAAAt	409
TBPF/ATATA.01	Avian C-type LTR TATA box	4520-4529	(+)	0.896	0.809	cTATGTAtgc	410
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	4531-4542	(-)	0.750	0.776	caTAGTtaactg	411
GATA/GATA3.02	GATA-binding factor 3	4544-4553	(+)	1.000	0.904	ctAGATgtta	412
FKHD/XFD3.01	Xenopus fork head domain factor	4545-4558	(-)	1.000	0.836	aaggttAACAtcta	413
MYT1/MYT1.01	MyT1 zinc finger transcription factor involved in primary neurogenesis	4548-4559	(-)	0.750	0.775	aaAGGTtaacat	414
AP4R/TAL1BETA-E47.01	Tal-1 beta/E47 heterodimer	4567-4582	(+)	1.000	0.884	aaacaCAGAtggaggc	415
EGRF/EGR1.01	Egr-1/Krox-24/NGFI-A immediate-early gene product	4614-4625	(+)	1.000	0.780	ttctgtGGCGg	416
ZFIA/ZID.01	zinc finger with interaction domain	4639-4651	(+)	1.000	0.918	cggGCTCcagcctc	417
CREB/TAXCREB.02	Tax/CREB complex	4657-4671	(+)	1.000	0.700	cgggatac TCGGggaa	418
CEBP/CEBP.02	C/EBP binding site	4660-4677	(+)	0.858	0.875	gattcggGGAAGacacg	419

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO:
E2F/E2F.01	E2F, involved in cell cycle regulation, interacts with Rb p107 protein	4662-4676	(+)	0.750	0.762	tctgcggGAAGacac	420
EBOX/NMYC.01	N-Myc	4671-4682	(-)	1.000	0.901	ttccCGTGtct	421
CLOX/CDP.01	cut-like homeodomain protein	4703-4714	(-)	0.757	0.751	tcATTAAatcaaa	422
HNF1/HNF1.01	hepatic nuclear factor 1	4706-4720	(+)	0.775	0.836	gATTAAatgattatt	423
CART/CART.01	Cart-1 (cartilage homeoprotein 1)	4713-4730	(+)	0.791	0.881	gatTTATtttgataacg	424
RPOA/LPOLYA.01	Lentiviral Poly A signal	4714-4721	(-)	1.000	0.963	aAATAAAAt	425
HNF1/HNF1.01	hepatic nuclear factor 1	4716-4730	(-)	1.000	0.798	cGTTAatcaaaataa	426
COMP/COMP1.01	COMP1, cooperates with myogenic proteins in multicomponent complex	4717-4740	(+)	0.791	0.785	tattttgATTAAacccgtcacagt	427
CREB/ATF.01	activating transcription factor	4726-4739	(-)	1.000	0.921	cgtTGACggcgfta	428
PAX5/PAX5.02	B-cell-specific activating protein	4733-4760	(-)	0.842	0.775	agggaactgtcttaaGGCgtactgtgac	429
PAX6/PAX6.01	Pax-6 paired domain protein	4735-4755	(+)	1.000	0.763	cacagtGACGccttagacag	430
CREB/ATF.01	activating transcription factor	4737-4750	(+)	1.000	0.906	cagTGACgccttag	431
WHZF/WHN.01	winged helix protein, involved in hair keratinization and thymus epithelium differentiation	4738-4748	(+)	1.000	0.974	agtGACGCctt	432
FKHD/FREAC4.01	Fork head Related Activator-4	4756-4771	(-)	1.000	0.775	cccggtgAACAggga	433
EGRF/NGFIC.01	nerve growth factor-induced protein C	4795-4806	(+)	0.763	0.835	caCGGAgggtgg	434
SPIF/SPI.01	stimulating protein 1 SPI, ubiquitous zinc finger transcription factor	4812-4824	(+)	1.000	0.895	tgggGGCGgacgc	435
GKLF/GKLF.01	gut-enriched Krueppel-like factor	4826-4839	(+)	0.950	0.921	ggaaagaggaGGGG	436
PCAT/CLTR CAAT.01	Mammalian C-type LTR CCAAT box	4827-4851	(-)	0.803	0.780	acCAAGgccccgccctctcttc	437
SPIF/SPI.01	stimulating protein 1 SPI, ubiquitous zinc finger transcription factor	4834-4846	(+)	1.000	0.985	gaggGGCGggggcc	438
RREB/RREB1.01	Ras-responsive element binding protein 1	4847-4860	(-)	1.000	0.806	cccCAcccgaccac	439
TEAF/TEF1.01	TEF-1 related muscle factor	4860-4871	(-)	1.000	0.850	ccCATTccatac	440
PAX5/PAX9.01	zebrafish PAX9 binding sites	4866-4889	(+)	0.866	0.780	aatgGCAgggtgggggggatggg	441

Table 2

NAME OF FAMILY/MATRIX	FURTHER INFORMATION	POSITION	STRAND	CORE SIM.	MATRIX SIM.	SEQUENCE	SEQ ID NO.
RREB/RREB1.01	Ras-responsive element binding protein 1	4868-4881	(-)	1.000	0.795	cCCCAccctgccca	442
EGRE/WT1.01	Wilms Tumor Suppressor	4874-4886	(+)	1.000	0.903	gggTGGGggggat	443
RREB/RREB1.01	Ras-responsive element binding protein 1	4877-4890	(-)	1.000	0.796	gCCCAtecccccca	444
MZF1/MZF1.01	MZF1	4878-4885	(+)	1.000	0.986	gggGGGga	445
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	4884-4896	(+)	1.000	0.937	gatgGGCGgggta	446
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	4900-4912	(+)	1.000	0.961	gatgGGCGggggcc	447
E2FF/E2F.03	E2F, involved in cell cycle regulation, interacts with RB p107 protein	4910-4922	(+)	0.806	0.788	gccCGGGaaattc	448
NOLF/OLF1.01	olfactory neuron-specific factor	4915-4936	(+)	1.000	0.843	ggaaafTCCcggcggggcag	449
NFKB/NFKAPPAB.01	NF-kappaB	4915-4924	(-)	1.000	1	GGGAatttc	450
IKRS/TK1.01	Ikaros 1, potential regulator of lymphocyte differentiation	4916-4928	(-)	1.000	0.916	gcgcGGGAatttc	451
HEN1/HEN1.01	HEN1	4944-4965	(+)	1.000	0.820	ctggctgtCAGCtgagccgcgc	452
AP4R/AP4.01	activator protein 4	4950-4959	(-)	1.000	0.977	ctCAGCtgac	453
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	4964-4976	(+)	1.000	0.945	gctgGGCGggggtc	454
EGRF/NGFIC.01	nerve growth factor-induced protein C	5018-5029	(-)	0.787	0.802	tgGCGGagggggg	455
EGRF/NGFIC.01	nerve growth factor-induced protein C	5024-5035	(-)	0.787	0.794	cgGCGGtgggcgg	456
EGRF/NGFIC.01	nerve growth factor-induced protein C	5030-5041	(-)	0.787	0.799	ggGCGGcggcggg	457
SP1F/SP1.01	stimulating protein 1 SP1, ubiquitous zinc finger transcription factor	5032-5044	(-)	1.000	0.898	ggcgGGCGgcgccgc	458
AP2F/AP2.01	activator protein 2	5037-5048	(+)	1.000	0.957	cgCCCGcgggca	459

As used herein, the term “*cis* elements capable of binding” refers to the ability of one or more of the described *cis* elements to specifically bind an agent. Such binding may be by any chemical, physical or biological interaction between the *cis* element and the agent, including, but not limited, to any covalent, steric, agostic, electronic and ionic interaction between the *cis* element and the agent. As used herein, the term “specifically binds” refers to the ability of the agent to bind to a specified *cis* element but not to wholly unrelated nucleic acid sequences. Regulatory region refers to the ability of a nucleic acid fragment, region or length to functionally perform a biological activity. The biological activity may be binding to the nucleic or specific DNA sequence. The biological activity may also modulate, enhance, inhibit or alter the transcription of a nearby coding region. The biological activity may be identified by a gel shift assay, in which binding to a nucleic acid fragment can be detected. Other methods of detecting the biological activity in a nucleic acid regulatory region are known in the art (see *Current Protocols in Molecular Biology*, for example).

Human transcription factor activator protein 1 (AP1) is a transcription factor that has been shown to regulate genes which are highly expressed in transformed cells such as stromelysin, *c-fos*, α_1 -anti-trypsin and collagenase. Gutman and Wasylyk, *EMBO J.* 9:7: 2241-2246 (1990); Martin *et al.*, *PNAS* 85: 5839-5843 (1988); Jones *et al.*, *Genes and Development* 2: 267-281 (1988); Faisst and Meyer, *Nucleic Acid Research* 20: 3-26 (1992); Kim *et al.*, *Molecular and Cellular Biology* 10: 1492-1497 (1990); Baumhueter *et al.*, *EMBO J.* 7: 2485-2493 (1988). The AP1 transcription factor has been associated with genes that are activated by 12-O-tetradecanolyphorbol-13-acetate (TPA). Sequences corresponding to an upstream motif or *cis* element capable of binding AP1 (SEQ ID NOs:

4, 15, 18, 24, 79, 119, 122, 178, 218, 343, and 348) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with certain embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of AP1 or its homologues, including, but not limited to, the concentration of AP1 or its homologues bound to an upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

A consensus sequence (GR/PR), recognized by both the glucocorticoid receptor of rat liver and the progesterone receptor from rabbit uterus, has been reported to be involved in glucocorticoid and progesterone-dependent gene expression. Von der Ahe *et al.*, *Nature* 313: 706-709 (1985). Sequences corresponding to a GC/PR upstream motif or *cis* element (SEQ ID NOs: 70 and 312) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of glucocorticoid or progesterone or their homologues, including, but not limited to, the concentration of glucocorticoid or progesterone or their homologues bound to an GC/PR upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

20990001-03060001

A consensus sequence for a vitellogenin gene-binding protein (VBP) upstream motif or *cis* element has been characterized. Iyer *et al.*, *Molecular and Cellular Biology* 11: 4863-4875 (1991). Expression of the VBP gene commences early in liver ontogeny and is not subject to circadian control. Sequences corresponding to an upstream motif or *cis* element capable of binding VBP (SEQ ID NOs: 112, 155, 239, 268 and 290) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of VBP or its homologues, including, but not limited to, the concentration of VBP or its homologues bound to an VBP upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

NFκB (or NFKB) is a transcription factor that is reportedly associated with a number of biological processes including T-cell activation and cytokine regulation. Lenardo *et al.*, *Cell* 58: 227-229 (1989). A consensus upstream motif or *cis* element capable of binding NFκB has been reported. Sequences corresponding to an upstream motif or *cis* element capable of binding NFκB (SEQ ID NOs: 166, 186, 221, 262, 294, 332 and 450) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of NFκB or its homologues, including, but not limited to, the concentration of NFκB or its homologues bound to an

upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

5 An NF1 motif or *cis* element has been identified which recognizes a family of at least six proteins. Courtois *et al.*, *Nucleic Acid Res.* 18: 57-64 (1990); Mul *et al.*, *J. Virol.* 64: 5510-5518 (1990); Rossi *et al.*, *Cell* 52: 405-414 (1988); Gounari *et al.*, *EMBO J.* 10: 559-566 (1990); Goyal *et al.*, *Mol. Cell Biol.* 10: 1041-1048 (1990); Mermond *et al.*, *Nature* 332: 557-561 (1988); Gronostajski *et al.*, *Molecular and Cellular Biology* 5: 964-971 (1985); Hennighausen *et al.*, *EMBO J.* 5: 1367-1371 (1986); Chodosh *et al.*, *Cell* 53: 11-24 (1988). The NF1 protein will bind to an NF1 motif or *cis* element either as a dimer (if the motif is palindromic) or as a single molecule (if the motif is not palindromic). The NF1 protein is induced by TGF β . Faisst and Meyer, *Nucleic Acid Research* 20: 3-26 (1992). Sequences corresponding to an upstream motif or *cis* element capable of binding NF1 (SEQ ID NOs: 117 and 194) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of NF1 or its homologues, including, but not limited to, the concentration of NF1 or its homologues bound to an upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

Sequences corresponding to an upstream motif or *cis* element capable of binding zinc (SEQ ID NOs: 217, 223 and 417) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of zinc. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

Human transcription factor activator protein 2 (AP2) is a transcription factor that has been shown to bind to Sp1, nuclear factor 1 (NF1) and simian virus 40 transplanta-
(SV40 T) antigen binding sites. It is developmentally regulated. Williams and Tijan, *Gene Dev.* 5: 670-682 (1991); Mitchell *et al.*, *Genes Dev.* 5: 105-119 (1991); Coutois *et al.*, *Nucleic Acid Research* 18: 57-64 (1990); Comb *et al.*, *Nucleic Acid Research* 18: 3975-3982 (1990); Winings *et al.*, *Nucleic Acid Research* 19: 3709-3714 (1991). Sequences corresponding to an upstream motif or *cis* element capable of binding AP2 (SEQ ID NOs: 327, 374, and 463) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of AP2 or its homologues, including, but not limited to, the concentration of AP2 or its homologues bound to an upstream motif or *cis* element. Such agents may be useful in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of

glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

The sex-determining region of the Y chromosome gene, *sry*, is expressed in the fetal mouse for a brief period, just prior to testis differentiation. SRY is a DNA binding protein known to bind to a CACA-rich region in the *sry* gene. Vriza *et al.*, *Biochemistry and Molecular Biology International* 37: 1137-1146 (1995). Sequences corresponding to an upstream motif or *cis* element capable of binding SRY (SEQ ID NOs: 335 and 393) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of SRY or its homologues, including, but not limited to, the concentration of SRY or its homologues bound to an upstream motif or *cis* element. Such agents may be useful in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

Normal liver and differentiated hepatoma cell lines contain a hepatocyte-specific nuclear factor (HNF-1) which binds *cis*-acting element sequences within the promoters of the alpha and beta chains of fibrinogen and alpha 1-antitrypsin. Baumhueter *et al.*, *EMBO J.* 8: 2485-2493. Sequences corresponding to an HNF-1 upstream motif or *cis* element (SEQ ID NOs: 126, 263, 423 and 426) are located in the optineurin promoter (SEQ ID NO: 1) at the respective residues indicated in Table 2. In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of

HNF-1 or its homologues, including, but not limited to, the concentration of HNF-1 or its homologues bound to an HNF-1 upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

Alu repetitive elements are unique to primates and are interspersed within the human genome with an average spacing of 4Kb. While some *Alu* sequences are actively transcribed by polymerase III, certain mRNA transcripts may also contain *Alu*-derived sequences in 5' or 3' untranslated regions. Jurka and Mikahanjaja, *J. Mol. Evolution* 32: 105-121 (1991); Claveria and Makalowski, *Nature* 371: 751-752 (1994). Sequences corresponding to an *Alu* upstream motif or *cis* element (SEQ ID NOs: 462 and 463) are located in the optineurin promoter (SEQ ID NO: 1) at residues 1002 through 1328 and 2288 through 2588, respectively, as depicted in Figure 3 by a dotted line above the nucleotides.

In accordance with the embodiments of the present invention, transcription of optineurin molecules can be effected by agents capable of altering the biochemical properties or concentration of nuclear factors or their homologues, including, but not limited to, the concentration of nuclear factors or their homologues bound to an *Alu* upstream motif or *cis* element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such agents can be used in the treatment of glaucoma.

Sequences corresponding to repeat elements (SEQ ID NOs: 460 and 461) are located in the optineurin promoter (SEQ ID NO: 1) at residues 598 through 878, and 938 through 957, respectively, as depicted in Figure 3 by a dotted line above the nucleotides.

In accordance with the embodiments of the present invention, transcription of optineurin

5 molecules can be effected by agents capable of altering the biochemical properties or concentration of nuclear factors or their homologues, including, but not limited to, the concentration of nuclear factors or their homologues bound to a repeat element. Such agents can be used in the study of glaucoma pathogenesis. In another embodiment, such agents can also be used in the study of glaucoma prognosis. In another embodiment such

10 agents can be used in the treatment of glaucoma.

Agents of the invention include nucleic acid molecules. In one aspect of the present invention the nucleic acid molecule is an optineurin promoter. An example of an optineurin promoter is the nucleic acid sequence set forth in SEQ ID NO: 1. In a preferred aspect of the present invention, the optineurin promoter comprises a fragment of

15 SEQ ID NO: 1 that itself comprises at least one ATG initiation codon and includes preferably between 100 and 500 consecutive nucleotides, more preferably between 200 and 1000 consecutive nucleotides, and most preferably between 500 and 5,000 consecutive nucleotides of SEQ ID NO: 1. In a particularly preferred embodiment, the optineurin promoter fragment comprises at least 150 bases upstream of the TATA-box.

20 More preferably, the optineurin promoter fragment is at least 15 consecutive nucleotides but not more than 1500 consecutive nucleotides of SEQ ID NO: 1 in length. In a preferred embodiment, the optineurin promoter fragment is at least 20 consecutive nucleotides but not more than 1500 consecutive nucleotides of SEQ ID NO: 1 in length.

In one embodiment the nucleic acid molecule is a DNA molecule. In another embodiment the nucleic acid molecule is an RNA molecule, more preferably an mRNA molecule. In a further embodiment the nucleic acid molecule is a double stranded molecule. In another further embodiment the nucleic acid molecule is a single stranded molecule.

In one embodiment, the nucleic acid molecule comprises one or more of the *cis* elements listed in Table 2. In another embodiment, the nucleic acid molecule comprises two or more of the *cis* elements listed in Table 2. In a further embodiment, the nucleic acid molecule comprises three, four, five, about ten, about fifteen or more, or between 3 and 3, 4 and 6, 5 and 7, 6 and 9, 10 and 15 or 20 and 30 of the *cis* elements listed in Table 2.

The present invention provides nucleic acid molecules that hybridize to the above-described nucleic acid molecules. Nucleic acid hybridization is a technique well known to those of skill in the art of DNA manipulation. The hybridization properties of a given pair of nucleic acids is an indication of their similarity or identity.

The nucleic acid molecules preferably hybridize, under low, moderate, or high stringency conditions, with a nucleic acid sequence selected from: (1) any of SEQ ID NOs: 3 through 463. In another aspect, the nucleic acid molecules preferably hybridize, under low, moderate, or high stringency conditions, with a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 and its complement.

The hybridization conditions typically involve nucleic acid hybridization in about 0.1X to about 10X SSC (diluted from a 20X SSC stock solution containing 3 M sodium chloride and 0.3 M sodium citrate, pH 7.0 in distilled water), about 2.5X to about 5X

Denhardt's solution (diluted from a 50X stock solution containing 1% (w/v) bovine serum albumin, 1% (w/v) ficoll, and 1% (w/v) polyvinylpyrrolidone in distilled water), about 10 mg/mL to about 100 mg/mL fish sperm DNA, and about 0.02% (w/v) to about 0.1% (w/v) SDS, with an incubation at about 20°C to about 70°C for several hours to
5 overnight. The stringency conditions are preferably provided by 6X SSC, 5X Denhardt's solution, 100 mg/mL fish sperm DNA, and 0.1% (w/v) SDS, with an incubation at 55°C for several hours.

The hybridization is generally followed by several wash steps. The wash compositions generally comprise 0.1X to about 10X SSC, and 0.01% (w/v) to about 0.5%
10 (w/v) SDS with a 15 minute incubation at about 20°C to about 70°C. Preferably, the nucleic acid segments remain hybridized after washing at least one time in 0.1X SSC at 65°C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 X SSC at 50°C to a high stringency of about 0.2 X SSC at 65°C. In addition, the temperature in the wash step can be increased from low stringency
15 conditions at room temperature, about 22°C, to high stringency conditions at about 65°C. Both temperature and salt may be varied, or either the temperature or the salt concentration may be held constant while the other variable is changed.

Low stringency conditions may be used to select nucleic acid sequences with lower sequence identities to a target nucleic acid sequence. One may wish to employ
20 conditions such as about 6.0 X SSC to about 10 X SSC, at temperatures ranging from about 20°C to about 55°C, and preferably a nucleic acid molecule will hybridize to one or more of the above-described nucleic acid molecules under low stringency conditions of about 6.0 X SSC and about 45°C. In a preferred embodiment, a nucleic acid molecule

will hybridize to one or more of the above-described nucleic acid molecules under moderately stringent conditions, for example at about 2.0 X SSC and about 65°C. In a particularly preferred embodiment, a nucleic acid molecule of the present invention will hybridize to one or more of the above-described nucleic acid molecules under high stringency conditions such as 0.2 X SSC and about 65°C.

In an alternative embodiment, the nucleic acid molecule comprises a nucleic acid sequence that is greater than 85% identical, and more preferably greater than 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to a nucleic acid sequence of the present invention, preferably one selected from the group consisting of SEQ ID NO: 1, fragments of SEQ ID NO: 1 that comprise at least 20 consecutive nucleotides but not more than 1500 consecutive nucleotides of the sequence of SEQ ID NO: 1, and complements thereof.

The percent identity is preferably determined using the "Best Fit" or "Gap" program of the Sequence Analysis Software Package™ (Version 10; Genetics Computer Group, Inc., University of Wisconsin Biotechnology Center, Madison, WI). "Gap" utilizes the algorithm of Needleman and Wunsch to find the alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. "BestFit" performs an optimal alignment of the best segment of similarity between two sequences and inserts gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman. The percent identity calculations may also be performed using the Megalign program of the LASERGENE bioinformatics computing suite (default parameters, DNASTAR Inc., Madison, Wisconsin). The percent identity is most preferably determined using the "Best Fit" program using default parameters.

The present invention also provides nucleic acid molecule fragments that hybridize to the above-described nucleic acid molecules and complements thereof, fragments of nucleic acid molecules that exhibit greater than 80%, 85%, 90%, 95% or 99% sequence identity with a nucleic acid molecule of the present invention.

5 Fragment nucleic acid molecules may consist of significant portion(s) of, or indeed most of, the nucleic acid molecules of the invention. In an embodiment, the fragments are between 3000 and 1000 consecutive nucleotides, 1800 and 150 consecutive nucleotides, 1500 and 500 consecutive nucleotides, 1300 and 250 consecutive nucleotides, 1000 and 200 consecutive nucleotides, 800 and 150 consecutive nucleotides,
10 500 and 100 consecutive nucleotides, 300 and 75 consecutive nucleotides, 100 and 50 consecutive nucleotides, 50 and 25 consecutive nucleotides, or 20 and 10 consecutive nucleotides long of a nucleic molecule of the present invention.

In another embodiment, the fragment comprises at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 500, or 750 consecutive nucleotides of a nucleic acid sequence of
15 the present invention. In another embodiment, the fragment comprises at least 12, 15, 18, 20, 25, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450 but not more 500, 550, 600, 650, 700, 750, 800, 1000, 1200, 1400, or 1500 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 and complements thereof.

Any of a variety of methods may be used to obtain one or more of the above-
20 described nucleic acid molecules. Automated nucleic acid synthesizers may be employed for this purpose. In lieu of such synthesis, the disclosed nucleic acid molecules may be used to define a pair of primers that can be used with the polymerase chain reaction to amplify and obtain any desired nucleic acid molecule or fragment.

Short nucleic acid sequences having the ability to specifically hybridize to complementary nucleic acid sequences may be produced and utilized in the present invention, *e.g.*, as probes to identify the presence of a complementary nucleic acid sequence in a given sample. Alternatively, the short nucleic acid sequences may be used
5 as oligonucleotide primers to amplify or mutate a complementary nucleic acid sequence using PCR technology. These primers may also facilitate the amplification of related complementary nucleic acid sequences (*e.g.*, related sequences from other species).

Use of these probes or primers may greatly facilitate the identification of transgenic cells or organisms which contain the presently disclosed promoters and
10 structural nucleic acid sequences. Such probes or primers may also, for example, be used to screen cDNA or genomic libraries for additional nucleic acid sequences related to or sharing homology with the presently disclosed promoters and structural nucleic acid sequences. The probes may also be PCR probes, which are nucleic acid molecules capable of initiating a polymerase activity while in a double-stranded structure with
15 another nucleic acid.

A primer or probe is generally complementary to a portion of a nucleic acid sequence that is to be identified, amplified, or mutated and of sufficient length to form a stable and sequence-specific duplex molecule with its complement. The primer or probe preferably is about 10 to about 200 nucleotides long, more preferably is about 10 to about
20 100 nucleotides long, even more preferably is about 10 to about 50 nucleotides long, and most preferably is about 14 to about 30 nucleotides long.

The primer or probe may, for example without limitation, be prepared by direct chemical synthesis, by PCR (U.S. Patent Nos. 4,683,195 and 4,683,202), or by excising

the nucleic acid specific fragment from a larger nucleic acid molecule. Various methods for determining the structure of PCR probes and PCR techniques exist in the art.

Computer-generated searches using programs such as Primer3 (www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi), STSPipeline (www-genome.wi.mit.edu/cgi-bin/www-

5 STS_Pipeline), or GeneUp (Pesole *et al.*, *BioTechniques* 25:112-123, 1998), for example, can be used to identify potential PCR primers.

Nucleic acid agents of the present invention may also be employed to obtain other optineurin nucleic acid molecules. Such molecules include the optineurin-encoding nucleic acid molecules of non-human animals (particularly cats, monkeys, rodents and
10 dogs), fragments thereof, and promoters and flanking sequences. Such molecules can readily be obtained by using the above-described primers to screen cDNA or genomic libraries obtained from non-human species. Methods for forming such libraries are known in the art.

Any of the nucleic acid agents of the invention may be linked with additional
15 nucleic acid sequences to encode fusion proteins. The additional nucleic acid sequence preferably encodes at least one amino acid, peptide, or protein. Many possible fusion combinations exist. For instance, the fusion protein may provide a “tagged” epitope to facilitate detection of the fusion protein, such as GST, GFP, FLAG, or polyHIS. Such fusions preferably encode between 1 and 50 amino acids, more preferably between 5 and
20 30 additional amino acids, and even more preferably between 5 and 20 amino acids.

Alternatively, the fusion may provide regulatory, enzymatic, cell signaling, or intercellular transport functions. For example, a sequence encoding a signal peptide may be added to direct a fusion protein to a particular organelle within a eukaryotic cell. Such

fusion partners preferably encode between 1 and 1000 additional amino acids, more preferably between 5 and 500 additional amino acids, and even more preferably between 10 and 250 amino acids.

The above-described protein or peptide molecules may be produced via chemical synthesis, or more preferably, by expression in a suitable bacterial or eukaryotic host. Suitable methods for expression are described by Sambrook *et al.*, *supra*, or similar texts. Fusion protein or peptide molecules of the invention are preferably produced via recombinant means. These proteins and peptide molecules may be derivatized to contain carbohydrate or other moieties (such as keyhole limpet hemocyanin, *etc.*).

10 B. Recombinant Vectors and Constructs

Exogenous genetic material may be transferred into a host cell by use of a vector or construct designed for such a purpose. Preferred exogenous genetic material is a nucleic acid molecule of the present invention, more preferred exogenous genetic material is an optineurin promoter sequence, and even more preferred exogenous genetic material is a nucleic acid molecule comprising SEQ ID NO: 1.

Any of the nucleic acid sequences described above may be provided in a recombinant vector. As used herein, "vector" refers to a plasmid, cosmid, bacteriophage, BAC, YAC, or virus that carries exogenous DNA into a host organism. A plasmid may be a linear or a closed circular plasmid. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host. Means for preparing recombinant vectors are well known in the art.

20090928T 100912Z . 030602

Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences encoding HCV epitopes into the host genome. For example, another vector used to express foreign DNA is vaccinia virus. Such heterologous DNA is generally inserted into a gene which is non-essential to the virus, for example, the thymidine kinase gene (tk), which also provides a selectable marker. Expression of the HCV polypeptide then occurs in cells or animals which are infected with the live recombinant vaccinia virus.

In general, plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell are used in connection with bacterial hosts. The vector ordinarily carries a replication site, as well as marking sequences that are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically transformed using pBR322, which contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid or phage, also generally contains, or is modified to contain, promoters that can be used by the microbial organism for expression of the selectable marker genes.

A construct or vector may include a promoter, *e.g.*, a recombinant vector typically comprises, in a 5' to 3' orientation: a promoter to direct the transcription of a nucleic acid sequence of interest and a nucleic acid sequence of interest. Suitable promoters include, but are not limited to, those described herein. The recombinant vector may further comprise a 3' transcriptional terminator, a 3' polyadenylation signal, other untranslated nucleic acid sequences, transit and targeting nucleic acid sequences, selectable markers, enhancers, and operators, as desired.

The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication.

5 For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Alternatively, the vector may be one which, when introduced into the cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. This integration may be the result of homologous or non-homologous recombination.

10 Integration of a vector or nucleic acid into the genome by homologous recombination, regardless of the host being considered, relies on the nucleic acid sequence of the vector. Typically, the vector contains nucleic acid sequences for directing integration by homologous recombination into the genome of the host. These nucleic acid sequences enable the vector to be integrated into the host cell genome at a
15 precise location or locations in one or more chromosomes. To increase the likelihood of integration at a precise location, there should be preferably two nucleic acid sequences that individually contain a sufficient number of nucleic acids, preferably 400 bp to 1500 bp, more preferably 800 bp to 1000 bp, which are highly homologous with the corresponding host cell target sequence. This enhances the probability of homologous
20 recombination. These nucleic acid sequences may be any sequence that is homologous with a host cell target sequence and, furthermore, may or may not encode proteins.

Promoters

In addition to the optineurin promoters described herein, other promoter sequences can be utilized in a vector or other nucleic acid molecule. In a preferred aspect, the promoter is operably linked to another nucleic acid molecule. The promoters
5 may be selected on the basis of the cell type into which the vector will be inserted. The promoters may also be selected on the basis of their regulatory features, *e.g.*, enhancement of transcriptional activity, inducibility, tissue specificity, and developmental stage-specificity. Additional promoters that may be utilized are described, for example, in Bernoist and Chambon, *Nature* 290:304-310 (1981); Yamamoto *et al.*, *Cell* 22:787-
10 797 (1980); Wagner *et al.*, *PNAS* 78:1441-1445 (1981); Brinster *et al.*, *Nature* 296:39-42 (1982).

Suitable promoters for mammalian cells are also known in the art and include viral promoters, such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), cytomegalovirus (CMV), and bovine papilloma virus (BPV), as well
15 as mammalian cell-derived promoters. Other preferred promoters include the hematopoietic stem cell-specific, *e.g.*, CD34, glucose-6-phosphatase, interleukin-1 alpha, CD11c integrin gene, GM-CSF, interleukin-5R alpha, interleukin-2, c-fos, h-ras and DMD gene promoters. Other promoters include the herpes thymidine kinase promoter, and the regulatory sequences of the metallothionein gene.

20 Inducible promoters suitable for use with bacteria hosts include the β -lactamase and lactose promoter systems, the arabinose promoter system, alkaline phosphatase, a tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. However, other known bacterial inducible promoters are suitable. Promoters for use in

bacterial systems also generally contain a Shine-Dalgarno sequence operably linked to the DNA encoding the polypeptide of interest.

Additional Nucleic Acid Sequences of Interest

The recombinant vector may also contain one or more additional nucleic acid sequences of interest. These additional nucleic acid sequences may generally be any sequences suitable for use in a recombinant vector. Such nucleic acid sequences include, without limitation, any of the nucleic acid sequences, and modified forms thereof, described above. The additional nucleic acid sequences may also be operably linked to any of the above described promoters. The one or more additional nucleic acid sequences may each be operably linked to separate promoters. Alternatively, the additional nucleic acid sequences may be operably linked to a single promoter (*i.e.* a single operon).

The additional nucleic acid sequences include, without limitation, those encoding gene products which are toxic to a cell such as the diphtheria A gene product.

Alternatively, the additional nucleic acid sequence may be designed to down-regulate a specific nucleic acid sequence. This is typically accomplished by operably linking the additional nucleic acid sequence, in an antisense orientation, with a promoter. One of ordinary skill in the art is familiar with such antisense technology. Any nucleic acid sequence may be negatively regulated in this manner. Preferable target nucleic acid sequences include SEQ ID NOs: 3 through 463.

Selectable and Screenable Markers

A vector or construct may also include a selectable marker. Selectable markers may also be used to select for organisms or cells that contain the exogenous genetic

material. Examples of such include, but are not limited to: a *neo* gene, which codes for kanamycin resistance and can be selected for using kanamycin, GUS, green fluorescent protein (GFP), neomycin phosphotransferase II (*nptII*), luciferase (LUX), or an antibiotic resistance coding sequence.

5 A vector or construct may also include a screenable marker. Screenable markers may be used to monitor expression. Exemplary screenable markers include: a β -glucuronidase or *uidA* gene (GUS) which encodes an enzyme for which various chromogenic substrates are known; a β -lactamase gene, a gene which encodes an enzyme for which various chromogenic substrates are known (*e.g.*, PADAC, a chromogenic
10 cephalosporin); a luciferase gene; a tyrosinase gene, which encodes an enzyme capable of oxidizing tyrosine to DOPA and dopaquinone which in turn condenses to melanin; and α -galactosidase, which will turn a chromogenic α -galactose substrate.

Included within the terms “selectable or screenable marker genes” are also genes which encode a secretable marker whose secretion can be detected as a means of
15 identifying or selecting for transformed cells. Examples include markers which encode a secretable antigen that can be identified by antibody interaction, or even secretable enzymes which can be detected catalytically. Secretable proteins fall into a number of classes, including small, diffusible proteins which are detectable, (*e.g.*, by ELISA), or small active enzymes which are detectable in extracellular solution (*e.g.*, α -amylase, β -
20 lactamase, phosphinothricin transferase). Other possible selectable and/or screenable marker genes will be apparent to those of skill in the art.

C. Transgenic Organisms, Transformed and Transfected Host Cells

One or more of the nucleic acid molecules or recombinant vectors of the invention may be used in transformation or transfection. For example, exogenous genetic material may be transferred into a cell or organism. In a preferred embodiment, the exogenous
5 genetic material includes a nucleic acid molecule of the present invention, preferably a nucleic acid molecule of an optineurin promoter. In another preferred embodiment, the nucleic acid molecule has a sequence selected from the group consisting of SEQ ID NO: 1, fragments of SEQ ID NO: 1 that comprise at least 20 consecutive nucleotides but not more than 1500 consecutive nucleotides of the sequence of SEQ ID NO: 1, and
10 complements thereof.

The invention is also directed to transgenic or transfected organisms and transformed or transfected host cells which comprise, in a 5' to 3' orientation, a promoter operably linked to a heterologous nucleic acid sequence of interest. Additional nucleic acid sequences may be introduced into the organism or host cell, such as 3'
15 transcriptional terminators, 3' polyadenylation signals, other untranslated nucleic acid sequences, signal or targeting sequences, selectable markers, enhancers, and operators. Preferred nucleic acid sequences of the present invention, including recombinant vectors, structural nucleic acid sequences, promoters, and other regulatory elements, are described herein. Another embodiment of the invention is directed to a method of producing such
20 transgenic organisms which generally comprises the steps of selecting a suitable organism, transforming the organism with a recombinant vector, and obtaining the transformed organism.

Transfer of a nucleic acid that encodes a protein can result in expression or overexpression of that protein in a transformed cell or transgenic organism. One or more of the proteins or fragments thereof encoded by nucleic acid molecules of the invention may be overexpressed in a transformed cell or transgenic organism. Such expression or overexpression may be the result of transient or stable transfer of the exogenous genetic material.

The expressed protein may be detected using methods known in the art that are specific for the particular protein or fragment. These detection methods may include the use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example using the antibodies to the protein. The techniques of enzyme assay and immunoassay are well known to those skilled in the art.

The resulting protein may be recovered by methods known in the arts. For example, the protein may be recovered from the nutrient medium by procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The recovered protein may then be further purified by a variety of chromatographic procedures, *e.g.*, ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like. Reverse-phase high performance liquid chromatography (RP-HPLC), optionally employing hydrophobic RP-HPLC media, *e.g.*, silica gel, further purify the protein. Combinations of methods and means can also be employed to provide a substantially purified recombinant polypeptide or protein.

Technology for introduction of nucleic acids into cells is well known to those of skill in the art. Common methods include chemical methods, microinjection, electroporation (U.S. Patent No. 5,384,253), particle acceleration, viral vectors, and

receptor-mediated mechanisms. Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts and regeneration of the cell wall. The various techniques for transforming mammalian cells are also well known.

There are many methods for introducing transforming DNA segments into cells, but not all are suitable for delivering DNA to eukaryotic cells. Suitable methods include virtually any method by which DNA can be introduced into a cell, such as by direct delivery of DNA, by desiccation/inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, by chemical transfection, by lipofection or liposome-mediated transfection, by calcium chloride-mediated DNA uptake, etc. In certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like.

A transformed or transfected host cell may generally be any cell which is compatible with the present invention. A transformed or transfected host organism or cell can be or derived from a cell or organism such as a mammalian cell, mammal, fish cell, fish, bird cell, bird, fungal cell, fungus, or bacterial cell. Preferred host and transformants include: fungal cells such as *Aspergillus*, yeasts, mammals, particularly murine, bovine and porcine, insects, bacteria, and algae. Methods to transform and transfect such cells or organisms are known in the art. See, e.g., EP 238023; Becker and Guarente, in: Abelson and Simon (eds.), *Guide to Yeast Genetics and Molecular Biology, Methods Enzymol.*

194: 182-187, Academic Press, Inc., New York; Bennett and LaSure (eds.), *More Gene Manipulations in Fungi*, Academic Press, CA, 1991; Hinnen *et al.*, *PNAS* 75:1920, 1978; Ito *et al.*, *J. Bacteriology* 153:163, 1983; Malardier *et al.*, *Gene* 78:147-156, 1989; Yelton *et al.*, *PNAS* 81:1470-1474, 1984. Mammalian cell lines available as hosts for expression

are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC, Manassas, VA), such as HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells and a number of other cell lines. Non-limiting examples of suitable mammalian host cell lines include those shown

5 below in Table 3.

Table 3: Mammalian Host Cell Lines

Host Cell	Origin	Source
HepG-2	Human Liver Hepatoblastoma	ATCC HB 8065
CV-1	African Green Monkey Kidney	ATCC CCL 70
LLC-MK ₂	Rhesus Monkey Kidney	ATCC CCL 7
3T3	Mouse Embryo Fibroblasts	ATCC CCL 92
AV12-664	Syrian Hamster	ATCC CRL 9595
HeLa	Human Cervix Epitheloid	ATCC CCL 2
RPMI8226	Human Myeloma	ATCC CCL 155
H4IIEC3	Rat Hepatoma	ATCC CCL 1600
C127I	Mouse Fibroblast	ATCC CCL 1616
293	Human Embryonal Kidney	ATCC CRL 1573
HS-Sultan	Human Plasma Cell Plasmocytoma	ATCC CCL 1484
BHK-21	Baby Hamster Kidney	ATCC CCL 10
HTM	Human Trabecular Meshwork	Stamer*
hTERT-RPE1	Human Retinal Pigment Epithelial Cells	Clontech [†]
HCE	Human Corneal Epithelium	LSU Eye Center [‡]
B-3	Human Eye	CRL-11421
CHO-K1	Chinese Hamster Ovary	ATCC CCL 61

(*Stamer, *Current Eye Research* 20: 347-350 (2000). † Clontech, Palo Alto, California.

‡ LSU Eye Center, New Orleans, LA.)

A fungal host cell may, for example, be a yeast cell, a fungi, or a filamentous

10 fungal cell. In one embodiment, the fungal host cell is a yeast cell, and in a preferred embodiment, the yeast host cell is a cell of the species of *Candida*, *Kluyveromyces*,

Saccharomyces, *Schizosaccharomyces*, *Pichia* and *Yarrowia*. In another embodiment, the fungal host cell is a filamentous fungal cell, and in a preferred embodiment, the filamentous fungal host cell is a cell of the species of *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Myceliophthora*, *Mucor*, *Neurospora*, *Penicillium*, *Thielavia*,
5 *Tolypocladium* and *Trichoderma*.

Suitable host bacteria include archaeobacteria and eubacteria, especially eubacteria and most preferably *Enterobacteriaceae*. Examples of useful bacteria include *Escherichia*, *Enterobacter*, *Azotobacter*, *Erwinia*, *Bacillus*, *Pseudomonas*, *Klebsiella*, *Proteus*, *Salmonella*, *Serratia*, *Shigella*, *Rhizobia*, *Vitreoscilla* and *Paracoccus*. Suitable
10 *E. coli* hosts include *E. coli* W3110 (ATCC 27325), *E. coli* 294 (ATCC 31446), *E. coli* B and *E. coli* X1776 (ATCC 31537) (American Type Culture Collection, Manassas, Virginia). Mutant cells of any of the above-mentioned bacteria may also be employed. These hosts may be used with bacterial expression vectors such as *E. coli* cloning and expression vector Bluescript™ (Stratagene, La Jolla, CA); pIN vectors (U.S. Patent
15 5,426,050), and pGEX vectors (Promega, Madison, Wis.), which may be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).

Preferred insect host cells are derived from *Lepidopteran* insects such as *Spodoptera frugiperda* or *Trichoplusia ni*. The preferred *Spodoptera frugiperda* cell line is the cell line Sf9 (ATCC CRL 1711). Other insect cell systems, such as the silkworm *B.*
20 *mori* may also be used. These host cells are preferably used in combination with Baculovirus expression vectors (BEVs), which are recombinant insect viruses in which the coding sequence for a chosen foreign gene has been inserted behind a baculovirus promoter in place of the viral gene, e.g., polyhedrin (U.S. Patent No. 4,745,051).

One aspect of the present invention relates to transgenic non-human animals having germline and/or somatic cells in which the biological activity of one or more genes are altered by a chromosomally incorporated transgene. In a preferred embodiment, the transgene encodes an antisense transcript which, when transcribed from the transgene, hybridizes with a portion of the optineurin promoter sequence, and inhibits expression of the optineurin gene.

In one embodiment, the present invention provides a desired non-human animal or an animal (including human) cell which contains a predefined, specific and desired alteration rendering the non-human animal or animal cell predisposed to glaucoma.

Specifically, the invention pertains to a genetically altered non-human animal (most preferably, a mouse), or a cell (either non-human animal or human) in culture, that expresses an antisense sequence directed to the optineurin promoter. Animals that express an antisense sequence directed to the optineurin promoter may exhibit a higher susceptibility to glaucoma or other ophthalmic disorders. By way of example, a genetically altered mouse of this type is able to serve as a model for hereditary glaucomas and as a test animal for glaucoma studies. Non-human animals or animal cells that express an antisense sequence directed to the optineurin promoter are able to serve as a glaucoma model. The invention additionally pertains to the use of such non-human animals or animal cells. Furthermore, it is contemplated that cells of the transgenic animals of the present invention can include other transgenes.

D. Inhibition of Gene Expression

In one aspect the activity or expression of an optineurin molecule is reduced by affecting the activity of the optineurin promoter. In a preferred aspect, the activity or

expression of an optineurin molecule is reduced by greater than 50%, 60%, 70%, 80% or 90% by the introduction into a recipient cell or host of an agent of the invention.

Antisense approaches are a way of preventing or reducing gene function by targeting the genetic material. The objective of the antisense approach is to use a sequence complementary to the target gene or its promoter to block its expression and create a mutant cell line or organism in which the level of a single chosen protein is selectively reduced or abolished. Antisense techniques have several advantages over other 'reverse genetic' approaches. The site of inactivation and its developmental effect can be manipulated by the choice of promoter for antisense genes or by the timing of external application or microinjection. Antisense can manipulate its specificity by selecting either unique regions of the target gene or regions where it shares homology to other related genes.

Under one embodiment, the process involves the introduction and expression of an antisense gene sequence. Such a sequence is one in which part or all of the normal gene sequences are placed under a promoter in inverted orientation so that the 'wrong' or complementary strand is transcribed into a noncoding antisense RNA that hybridizes with the target mRNA and interferes with its expression. An antisense vector can be constructed by standard procedures and introduced into cells by transformation, transfection, electroporation, microinjection, infection, *etc.* The type of transformation and choice of vector will determine whether expression is transient or stable. The promoter used for the antisense gene may influence the level, timing, tissue, specificity, or inducibility of the antisense inhibition.

One aspect of the invention relates to the use of nucleic acids, *e.g.*, SEQ ID NOs: 1 through 463, fragments thereof, or sequences complementary thereto, in antisense therapy. As used herein, antisense therapy refers to administration or *in situ* generation of oligonucleotide molecules or their derivatives which specifically hybridize (*e.g.*, bind) under physiological conditions with the cellular mRNA and/or genomic DNA, thereby inhibiting transcription and/or translation of that gene. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, antisense therapy refers to the range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

An antisense construct of the present invention can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which is complementary to at least a unique portion of the cellular mRNA. Alternatively, the antisense construct is an oligonucleotide probe which is generated *ex vivo* and which, when introduced into the cell, causes inhibition of expression by hybridizing with the mRNA and/or genomic sequences of a subject nucleic acid. Such oligonucleotide probes are preferably modified oligonucleotides which are resistant to endogenous nucleases, *e.g.*, exonucleases and/or endonucleases, and are therefore stable *in vivo*. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphorothioate and methylphosphonate analogs of DNA (*see also* U.S. Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy have been reviewed, for example, by Van der Krol *et al.*, *BioTechniques* 6:958-976 (1988); and Stein *et al.*, *Cancer Res* 48:2659-2668

(1988). With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, *e.g.*, between the -10 and +10 regions of the nucleotide sequence of interest, are preferred.

Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to mRNA. The antisense oligonucleotides will bind to the mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. In the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the mRNA, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well. *See Wagner, Nature 372:333 (1994).* Therefore, oligonucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a gene could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are typically less efficient inhibitors of

translation but could also be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of subject mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

5 Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is
10 envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

15 The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors), or agents
20 facilitating transport across the cell membrane (*see, e.g.*, Letsinger *et al.*, *PNAS* 86:6553-6556 (1989); Lemaitre *et al.*, *PNAS* 84:648-652 (1987); WO 88/09810) or the blood-brain barrier (*see, e.g.*, WO 89/10134), hybridization-triggered cleavage agents (*See, e.g.*, Krol *et al.*, *BioTechniques* 6:958-976 (1988)), or intercalating agents (*see, e.g.*, Zon, *Pharm.*

Res. 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, *etc.*

Antisense oligonucleotides may comprise at least one modified base moiety which

5 is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxytriethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-

10 methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,

15 uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Antisense oligonucleotides may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose. The antisense oligonucleotide can also contain a neutral peptide-

20 like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, *e.g.*, in Perry-O'Keefe *et al.*, *PNAS* 93:14670 (1996) and in Eglom *et al.*, *Nature* 365:566 (1993). One advantage of PNA oligomers is their capability to bind to complementary DNA essentially independently from the ionic strength of the medium

due to the neutral backbone of the DNA. In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet a further embodiment, the antisense oligonucleotide is an alpha-anomeric oligonucleotide. An alpha-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gautier *et al.*, *Nucl. Acids Res.* 15:6625-6641 (1987)). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, *Nucl. Acids Res.* 15:6131-12148 (1987)), or a chimeric RNA-DNA analogue (Inoue *et al.*, *FEBS Lett.* 215:327-330 (1987)).

Antisense molecules can be delivered to cells which express the target nucleic acid *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; *e.g.*, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (*e.g.*, antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs. Therefore, a preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts

of single stranded RNAs that will form complementary base pairs with the endogenous transcripts and thereby prevent translation of the target mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally
5 integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art, and can be plasmid, viral, or others known in the art for replication and expression in mammalian cells.

Expression of the sequence encoding the antisense RNA can be by any promoter
10 known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region, the promoter contained in the 3' long terminal repeat of Rous sarcoma virus, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene, etc. Any type of plasmid, cosmid, BAC, YAC or viral vector can
15 be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site; *e.g.*, the choroid plexus or hypothalamus. Alternatively, viral vectors can be used which selectively infect the desired tissue (*e.g.*, for brain, herpesvirus vectors may be used), in which case administration may be accomplished by another route (*e.g.*, systemically).

20 Antisense RNA, DNA, and ribozyme molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase

phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Moreover, various well-known modifications to nucleic acid molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

Endogenous gene expression can be reduced by inactivating or "knocking out" the gene or its promoter using targeted homologous recombination. (*E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321(1989)*). For example, a mutant, non-functional gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous gene (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express that gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the gene.

E. Pharmaceutical Compositions

Pharmaceutical compositions can comprise polynucleotides of the present invention. The pharmaceutical compositions will comprise a therapeutically effective amount of nucleic acid molecules of the present invention.

5 The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount
10 for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgment of the clinician.

15 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, *e.g.*, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

20 A therapeutically effective dose refers to that amount of active ingredient, for example, an optineurin promoter molecule or fragments thereof, antibodies of an optineurin promoter molecule, agonists, antagonists or inhibitors of the optineurin promoter, which ameliorates the symptoms or condition. Therapeutic efficacy and

toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio,

- 5 ED50/LD50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the
- 10 dosage form employed, sensitivity of the patient, and the route of administration.

- The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the
- 15 subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

- 20 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for

nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is
5 administered.

There is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, *e. g.*, Remington's Pharmaceutical Sciences, 17th ed. 1985). Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants, buffers, bacteriostats, and
10 solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for
15 administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids,
20 polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Other pharmaceutically acceptable

carriers include, but are not limited to, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, as well as combinations thereof.

- 5 Additionally, auxiliary substances, such as wetting or emulsifying agents, lubricants, preservatives, stabilizers, pH buffering substances, coloring, flavoring and the like, may be present in such vehicles.

Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid
10 vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid
15 salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. Pharmaceutically acceptable excipients can also be used therein.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions
20 that can be used in the methods of treatment. Optionally associated with such container(s) can be a notice or leaflet in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice or leaflet reflects approval by the agency of manufacture, use, or sale for human

administration. The pack or kit can contain a leaflet or be labeled with information regarding mode of administration, sequence of drug administration (*e.g.*, separately, sequentially, or concurrently), or the like. The pack or kit may also contain means for reminding the patient to take the therapy. The pack or kit may be a single unit dosage, a plurality of unit dosages, or a combination therapy.

In particular, the agents can be separated, mixed together in any combination, or present in a single vial or tablet. Agents assembled in a blister pack or other dispensing means is preferred. For the purpose of this invention, unit dosage is intended to mean a dosage that is dependent on the individual pharmacodynamics of each agent and administered in FDA approved dosages in standard time courses.

Delivery Methods

Once formulated, the pharmaceuticals compositions of the invention can be (1) administered directly to the subject; (2) delivered *ex vivo*, to cells derived from the subject; or (3) delivered *in vitro* for expression of recombinant proteins.

Methods for direct delivery of the compositions include, but are not limited to, subcutaneous, intraperitoneal, intraocular, intranasal, intravenous, intramuscular, intradermal, oral, intranasal, topical, intravesical, intrathecal, or delivered to the interstitial space of a tissue. In a preferred embodiment, the composition is introduced intraocularly by, for example, eye drops. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., WO 93/14778. Examples of cells useful in *ex vivo* applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells, and trabecular meshwork cells, particularly human trabecular meshwork cells.

Generally, delivery of nucleic acids for both *ex vivo* and *in vitro* applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

Preparation of antisense polypeptides is discussed above. Both the dose of the antisense composition and the means of administration are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. Administration of the therapeutic antisense agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic antisense composition contains an expression construct comprising a promoter and a polynucleotide segment of at least about 12, 22, 25, 30, or 35 contiguous nucleotides of the antisense strand of a nucleic acid. Within the expression construct, the polynucleotide segment is located downstream from the promoter, and transcription of the polynucleotide segment initiates at the promoter.

Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues is also used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis *et al.*, Trends in Biotechnol. (1993) 11:202-205; Chiou *et al.*, (1994) Gene

- 5 Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.); Wu & Wu, J. Biol. Chem. (1988) 263:621-24; Wu *et al.*, J. Biol. Chem. (1994) 269:542-46; Zenke *et al.*, PNAS (1990) 87:3655-59; Wu *et al.*, J. Biol. Chem. (1991) 266:338-42.

Preferably, receptor-mediated targeted delivery of therapeutic compositions containing antibodies of the invention is used to deliver the antibodies to specific tissue.

- 10 Therapeutic compositions containing antisense subgenomic polynucleotides are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 mg to about 2 mg, about 5 mg to about 500 mg, and about 20 mg to about 100 mg of DNA can also be used during a gene therapy protocol. Factors such as method of action
- 15 and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic nucleic acids. Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic nucleic acids or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions
- 20 of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect.

For genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in U.S. Pat. No. 5,654,173.

Therapeutic agents also include antibodies to proteins and polypeptides encoded by the subject nucleic acids, as described in U.S. Pat. No. 5,654,173.

5 Gene Delivery

The therapeutic nucleic acids of the present invention may be utilized in gene delivery vehicles. The gene delivery vehicle may be of viral or non-viral origin (see generally, Jolly, *Cancer Gene Therapy* 1:51-64 (1994); Kimura, *Human Gene Therapy* 5:845-852 (1994); Connelly, *Human Gene Therapy* 1:185-193 (1995); and Kaplitt, 10 *Nature Genetics* 6:148-153 (1994)). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches. Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or 15 regulated.

The present invention can employ recombinant retroviruses which are constructed to carry or express a selected nucleic acid molecule of interest. Retrovirus vectors that can be employed include those described in EP 0415731; EP 0345242; WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; WO 93/11230; WO 93/10218; Vile and 20 Hart, *Cancer Res.* 53:3860-3864 (1993); Vile and Hart, *Cancer Res.* 53:962-967 (1993); Ram *et al.*, *Cancer Res.* 53:83-88 (1993); Takamiya *et al.*, *J. Neurosci. Res.* 33:493-503 (1992); Baba *et al.*, *J. Neurosurg.* 79:729-735 (1993); U.S. Patent Nos. 5, 219,740 and

4,777,127; and GB Patent No. 2,200,651. Preferred recombinant retroviruses include those described in WO 91/02805.

Packaging cell lines suitable for use with the above-described retroviral vector constructs may be readily prepared (WO 95/30763 and WO 92/05266), and used to create
5 producer cell lines (also termed vector cell lines) for the production of recombinant vector particles. Within particularly preferred embodiments of the invention, packaging cell lines are made from human (such as HT1080 cells) or mink parent cell lines, thereby allowing production of recombinant retroviruses that can survive inactivation in human serum.

10 The present invention also employs alphavirus-based vectors that can function as gene delivery vehicles. Such vectors can be constructed from a wide variety of alphaviruses, including, for example, Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR
15 1249; ATCC VR-532). Representative examples of such vector systems include those described in U.S. Patent Nos. 5,091,309; 5,217,879; and 5,185,440; and WO 92/10578; WO 94/21792; WO 95/27069; WO 95/27044; and WO 95/07994.

Gene delivery vehicles of the present invention can also employ parvovirus such as adeno-associated virus (AAV) vectors. Representative examples include the AAV
20 vectors disclosed by Srivastava in WO 93/09239, Samulski *et al.*, *J. Vir.* 63:3822-3828 (1989); Mendelson *et al.*, *Virol.* (1988) 166:154-165; and Flotte *et al.*, PNAS 90:10613-10617 (1993).

Representative examples of adenoviral vectors include those described by Berkner, *Biotechniques* 6:616-627 (1988); Rosenfeld *et al.*, *Science* 252:431-434 (1991); WO 93/19191; Kolls *et al.*, *PNAS* 91:215-219 (1994); Kass-Eisler *et al.*, *PNAS* 90:11498-11502 (1993); Guzman *et al.*, *Circulation* 88:2838-2848 (1993); Guzman *et al.*, *Cir. Res.* 5 73:1202-1207 (1993); Zabner *et al.*, *Cell* 75:207-216 (1993); Li *et al.*, *Hum. Gene Ther.* 4:403-409 (1993); Cailaud *et al.*, *Eur. J. Neurosci.* 5:1287-1291 (1993); Vincent *et al.*, *Nat. Genet.* 5:130-134 (1993); Jaffe *et al.*, *Nat. Genet.* 1:372-378 (1992); and Levrero *et al.*, *Gene* 101:195-202 (1991). Exemplary adenoviral gene therapy vectors employable in this invention also include those described in WO 94/12649, WO 93/03769, WO 10 93/19191, WO 94/28938, WO 95/11984 and WO 95/00655. Administration of DNA linked to killed adenovirus as described in Curiel, *Hum. Gene Ther.* 3:147-154 (1992) may be employed.

Other gene delivery vehicles and methods may be employed, including polycationic condensed DNA linked or unlinked to killed adenovirus alone (Curiel, *Hum.* 15 *Gene Ther.* 3:147-154 (1992)); ligand linked DNA (Wu, *J. Biol. Chem.* 264:16985-16987 (1989)); eukaryotic cell delivery vehicles cells (U.S. Patent No. 6,287,792); deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun (U.S. Patent No. 5,149,655); ionizing radiation (U.S. Patent No. 5,206,152; WO 92/11033); and nucleic charge neutralization or fusion with cell membranes. Additional approaches are 20 described in Philip, *Mol. Cell Biol.* 14:2411-2418 (1994), and in Woffendin *et al.*, *PNAS* 91:11581-11585 (1994).

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Patent No. 5,580,859. Uptake efficiency

may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

- 5 Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422,120, WO 95/13796, WO 94/23697, WO 91/14445, and EP 0524968.

F. Diagnostic and Prognostic Assays

Agents of the present invention can be utilized in methods to determine, for example, without limitation, the presence or absence of a nucleic acid molecule in a
10 sample, and the level of nucleic acid molecule in a sample. Moreover, agents of the present invention can be utilized in methods for diagnosing glaucoma, methods for prognosing glaucoma, and methods for predicting a predisposition to glaucoma.

As used herein, the "Expression Response" manifested by a cell or tissue of an organism is said to be "altered" if it differs from the Expression Response of cells or
15 tissues not exhibiting the phenotype. To determine whether a Expression Response is altered, the Expression Response manifested by the cell or tissue of the organism exhibiting the phenotype is compared with that of a similar cell or tissue sample of an organism not exhibiting the phenotype. As will be appreciated, it is not necessary to re-determine the Expression Response of the cell or tissue sample of organisms not
20 exhibiting the phenotype each time such a comparison is made; rather, the Expression Response of a particular organism may be compared with previously obtained values of normal organisms.

Also as used herein, a "tissue sample" is any sample that comprises more than one cell. In a preferred aspect, a tissue sample comprises cells that share a common characteristic (e.g. derived from neurons, epidermis, muscle etc.). Preferred cells and tissue samples may be derived from bodily fluids including glaucomatous cell extract, fluid from the anterior chamber of the eye, blood, lymph, serum, amniotic fluid, and cerebrospinal fluid, or from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs. A test sample may be derived from adults, juveniles, and fetuses. Test samples from fetal cells or tissue can be obtained by appropriate methods, such as by amniocentesis or chorionic villus sampling. In a preferred embodiment, a sample is derived from bodily fluids such as glaucomatous cell extract, fluid from the anterior chamber of the eye, blood, lymph, and serum.

A number of methods can be used to compare the expression response between two or more samples of cells or tissue. These methods include hybridization assays, such as northern, RNase protection assays, and *in situ* hybridization. In a preferred method, the expression response is compared by PCR-type assays.

An advantage of *in situ* hybridization over certain other techniques for the detection of nucleic acids is that it allows an investigator to determine the precise spatial population. *In situ* hybridization may be used to measure the steady-state level of RNA accumulation. A number of protocols have been devised for *in situ* hybridization, each with tissue preparation, hybridization and washing conditions.

In situ hybridization also allows for the localization of proteins or mRNA within a tissue or cell. It is understood that one or more of the molecules of the invention, preferably one or more of the nucleic acid molecules or fragments thereof of the invention

or one or more of the antibodies of the invention may be utilized to detect the level or pattern of a protein or mRNA thereof by *in situ* hybridization.

In one aspect of the present invention, an evaluation can be conducted to determine whether a optineurin nucleic acid molecule is present. One or more of the
5 nucleic acid molecules of the present invention are utilized to detect the presence, type, or quantity of the nucleic acid molecule. Generally, such a method comprises: (a) obtaining cell or tissue sample of interest; and (b) selectively detecting the presence or absence, or ascertaining the level of a nucleic acid molecule.

As used herein, the term "presence" refers to when a molecule can be detected
10 using a particular detection methodology. Also as used herein, the term "absence" refers to when a molecule cannot be detected using a particular detection methodology.

The present invention also includes and provides a method for determining a level or pattern of a protein in an animal cell or animal tissue comprising (A) assaying the concentration of the protein in a first sample obtained from the animal cell or animal
15 tissue; (B) assaying the concentration of the protein in a second sample obtained from a reference animal cell or a reference animal tissue with a known level or pattern of the protein; and (C) comparing the assayed concentration of the protein in the first sample to the assayed concentration of the protein in the second sample.

Any method for analyzing proteins can be used to detect or measure levels of a
20 polypeptide. As an illustration, size differences can be detected by Western blots of protein extracts from the two tissues. Other changes, such as expression levels and subcellular localization, can also be detected immunologically, using antibodies to the corresponding protein. The expression pattern of any cell or tissue types can be

compared. Such comparison can also occur in a temporal manner. Another comparison can be made between difference developmental states of a tissue or cell sample.

More particularly, in one embodiment, mRNA in a cell or tissue sample can be detected by incubating mRNA molecules with cell or tissue sample extracts of an organism under conditions sufficient to permit nucleic acid hybridization. The detection of double-stranded probe-mRNA hybrid molecules is indicative of the presence of the mRNA; the amount of such hybrid formed is proportional to the amount of mRNA. Thus, such probes may be used to ascertain the level and extent of the mRNA production in an organism's cells or tissues. Such nucleic acid hybridization may be conducted under quantitative conditions (thereby providing a numerical value of the amount of the mRNA present). Alternatively, the assay may be conducted as a qualitative assay that indicates either that the mRNA is present, or that its level exceeds a user set, predefined value.

Alternatively, mRNA may be selectively detected using standard PCR or RT-PCR techniques such as those described herein. In another embodiment, polypeptide molecules of the present invention may be selectively detected using an immunological binding assay, *e.g.*, an *in situ* binding assay. In this regard, an antibody which selectively binds to a polypeptide of the present invention may be used. Optionally, the antibody may be labeled as described below to aid in detection.

More particularly, polypeptide molecules can be detected and/or quantified using any of a number of well recognized immunological binding assays (*see, e.g.*, U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, *see also* Methods in Cell Biology: Antibodies in Cell Biology, volume 37

(Asai, *ed.* 1993); Basic and Clinical Immunology (Stites & Terr, *eds.*, 7th ed. 1991).

Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice. The antibody may be produced by any of a number of means well known to those of skill in the art and as described above.

5 Immunoassays also often use a labeling agent to specifically bind to, and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent may be a labeled polypeptide or a labeled antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/polypeptide
10 complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, e.g.*, Kronval *et al.*, *J.*
15 *Immunol.*, 111:1401-1406 (1973); Akerstrom *et al.*, *J. Immunol.*, 135:2589-2542 (1985)). The labeling agent can be modified with a detectable moiety, such as biotin, to which another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art. A preferred label is a fluorescent label.

20 Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the

like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

Generally, immunoassays for detecting a polypeptide in a sample may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of antigen is directly measured. In one preferred “sandwich” assay, for example, the antibodies can be bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture the polypeptide present in the test sample. The polypeptide is thus immobilized, and is then bound by a labeling agent, such as a second antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, *e.g.*, streptavidin, to provide a detectable moiety.

Western blot (immunoblot) analysis may also be used to detect and quantify the presence of polypeptide in the sample. Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (*e.g.*, antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (*see Monroe et al., Amer. Clin. Prod. Rev.*, 5:34-41 (1986)).

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well

known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

5 The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well developed in the field of immunoassays and, in general, most any label useful in such methods can be
10 applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.*, DYNABEADS™), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (*e.g.*, ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (*e.g.*, horse
15 radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (*e.g.*, polystyrene, polypropylene, latex, etc.).

 Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this
20 case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

Thus, in one aspect of the present invention, provided are methods for diagnosing glaucoma in a sample obtained from a cell or a bodily fluid by detecting a polymorphism in a promoter region of the optineurin gene, comprising the steps of: (A) incubating under conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, the

5 marker nucleic acid molecule having a nucleic acid sequence that specifically hybridizes to a sequence selected from the group consisting of SEQ ID NO: 1 and a complement thereof, and a complementary nucleic acid molecule obtained from a sample, wherein nucleic acid hybridization between the marker nucleic acid molecule and the

10 complementary nucleic acid molecule permits the detection of said polymorphism; (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule; and (C) detecting the presence of the polymorphism, wherein the detection of the polymorphism is diagnostic of glaucoma.

Also provided by the present invention are methods for prognosing glaucoma in a sample obtained from a cell or a bodily fluid by detecting a polymorphism in a promoter

15 region of the optineurin gene, comprising the steps of: (A) incubating under conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, the marker nucleic acid molecule having a nucleic acid sequence that specifically hybridizes to a sequence selected from the group consisting of SEQ ID NO: 1 and complement thereof, and a

20 complementary nucleic acid molecule obtained from a sample, where nucleic acid hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule permits the detection of the polymorphism; (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule;

and (C) detecting the presence of the polymorphism, where the detection of the polymorphism is prognostic of glaucoma.

Further provided by the present invention are methods for diagnosing or prognosing glaucoma in a sample obtained from a cell or a bodily fluid by detecting a polymorphism in a promoter region of the optineurin gene, comprising the steps of: (A) incubating under conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, the marker nucleic acid molecule having a nucleic acid sequence that specifically hybridizes to a optineurin promoter sequence or its complement, and a complementary nucleic acid molecule obtained from a sample, where nucleic acid hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule permits the detection of the polymorphism; (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule; and (C) detecting the presence of the polymorphism, where the detection of the polymorphism is diagnostic or prognostic of glaucoma.

The methods of the present invention may be used to detect a single nucleotide polymorphism, and may further comprise a second marker nucleic acid molecule.

The present invention further provides methods for detecting the presence or absence of a SNP sequence variation in a sample containing DNA, comprising contacting a labeled nucleic acid capable of detecting a single nucleotide polymorphism selected from table 1 with the DNA of the sample under hybridization conditions and determining the presence of hybrid nucleic acid molecules comprising the labeled nucleic acid.

The cell or bodily fluid may comprise human trabecular meshwork cells, or may be selected from the group consisting of glaucomatous cell extract, fluid from the anterior

chamber of the eye, blood, lymph, and serum. The methods may further comprise amplifying the complementary nucleic acid molecule obtained from a sample using a nucleic acid amplification method, where the nucleic acid amplification method is selected from the group consisting of polymerase chain amplification, ligase chain
5 reaction, oligonucleotide ligation assay, thermal amplification, and transcription base amplification.

The diagnostic and prognostic methods described herein can, for example without limitation, utilize one or more of the detection methods described herein, including but not limited to northern blot analysis, standard PCR, reverse transcription-polymerase
10 chain reaction (RT-PCR), *in situ* hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry.

In one aspect, the method comprises *in situ* hybridization with a nucleic acid molecule of the present invention as a probe. This method comprises contacting the labeled hybridization probe with a sample of a given type of tissue potentially containing
15 glaucomatous or pre-glaucomatous cells as well as normal cells, and determining whether the probe labels some cells of the given tissue type to a degree significantly different (*e.g.*, by at least a factor of two, or at least a factor of five, or at least a factor of twenty, or at least a factor of fifty) than the degree to which it labels other cells of the same tissue type.

20 Alternatively, the above diagnostic assays may be carried out using antibodies which selectively detect a polypeptide of the present invention. Accordingly, in one embodiment, the assay includes contacting the proteins of the test cell with an antibody specific for a polypeptide of the present invention and determining the approximate

amount of immunocomplex formation. Such a complex can be detected by an assay for example without limitation an immunohistochemical assay, dot-blot assay, and an ELISA assay.

Immunoassays are commonly used to quantitate the levels of proteins in cell samples, and many other immunoassay techniques are known in the art. The invention is not limited to a particular assay procedure, and therefore is intended to include both homogeneous and heterogeneous procedures. Exemplary immunoassays which can be conducted according to the invention include fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). An indicator moiety, or label group, can be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method which are often dictated by the availability of assay equipment and compatible immunoassay procedures. General techniques to be used in performing the various immunoassays noted above are known to those of ordinary skill in the art.

G. Modulator Screening Assays

Another aspect of the invention is directed to the identification of agents capable of modulating one or more optineurin molecules. Such agents are herein referred to as “modulators” or “modulating compounds”. In this regard, the invention provides assays for determining compounds that modulate the function and/or expression of one or more optineurin molecules.

“Inhibitors,” “activators,” and “modulators” of optineurin molecules are used interchangeably to refer to inhibitory, activating, or modulating molecules which can be identified using *in vitro* and *in vivo* assays for optineurin activity and/or expression, *e.g.*, ligands, agonists, antagonists, and their homologs and mimetics.


5 Suitable modulators include, but are not limited to, hydroxamic acids, diclofenac, MMP inhibitors, macrocyclic anti-succinate hydroxamate derivatives, anti-angiogenics, tetracyclines, steroid inactivators of metalloproteinase translation, DNA binding (minor groove) compounds, peptide-like agents such as TIMPs, N-carboxyalkyl peptides, polyamines and glycosaminoglycans, non-steroidal anti-inflammatory drugs (NSAIDs),
10 corticosteroids, immunosuppressive agents, antibiotics, receptor antagonists, RNA aptamers, and antibodies.

 Anti-angiogenics comprise a class of compounds including growth factors, cytokines and peptides, which share characteristics such as the ability to inhibit angiogenesis, endothelial cell proliferation, migration, tube formation and
15 neovascularization. Preferred anti-angiogenics include endostatin and active collagen fragment derivatives, such as arresten (a 26 kDa NC1 domain of the alpha 1 chain of type IV collagen), thrombospondin, interleukin-12, angiostatin and active fragments and derivatives of plasminogen. *See Colorado et al., Cancer Research* 60(9):2520-26 (2000);
 Sunamura *et al., Pancreas* 20(3):227-33 (2000); Griscelli *et al., Proceedings of the*
20 *National Academy of Sciences U.S.A.*, 95(11):6367-72 (1998). Other preferred anti-angiogenics are growth factors such as basic fibroblast growth factor (bFGF), which may be used alone or in combination with other anti-angiogenics such as all-trans retinoic acid to stimulate native MMP inhibitors such as tissue inhibitor of metalloproteinases-1

(TIMP-1) protein. See Bigg *et al.*, *European Journal of Biochemistry* 267(13):4150-56 (2000).

Hydroxamic acid-based modulators are described in U.S. Patent No. 5,240,958, and preferably have the general formula:

5



where R¹ represents thienyl; R² represents a hydrogen atom or a C₁-C₆ alkyl, C₁-C₆ alkenyl, phenyl(C₁-C₆) alkyl, cycloalkyl(C₁-C₆)alkyl or cycloalkenyl(C₁-C₆)alkyl group; R³ represents an amino acid side chain or a C₁-C₆ alkyl, benzyl, (C₁-C₆alkoxy)benzyl or benzyloxy(C₁-C₆ alkyl) or benzyloxy benzyl group; R⁴ represents a
10 hydrogen atom or a C₁-C₆ alkyl group; R⁵ represents a hydrogen atom or a methyl group; n is an integer having the value 0, 1 or 2; and A represents a C₁-C₆ hydrocarbon chain, optionally substituted with one or more C₁-C₆ alkyl, phenyl or substituted phenyl groups; or a salt thereof.

Other hydroxamic acid-based modulators include phosphinamide-based
15 hydroxamic acids, peptidyl hydroxamic acids including p-NH₂-Bz-Gly-Pro-D-Leu-D-Ala-NHOH (FN-439), hydroxamic acids with a quaternary-hydroxy group, and succinate-derived hydroxamic acids related to batimastat. See, *e.g.*, Pikul *et al.*, *Journal of Medical Chemistry* 42(1):87-94 (1999); Odake *et al.*, *Biochem Biophys Res Commun* 199(3):1442-


46 (1994); Jacobson *et al.*, *Bioorganic Medical Chemistry Letters* 8(7):837-42 (1998);

Steinman *et al.*, *Bioorganic Medical Chemistry Letters* 8(16):2087-92 (1998).

Macrocyclic anti-succinate hydroxamate derivatives can also be effective modulators.

See Cherney *et al.*, *Bioorganic Medical Chemistry Letters* 9(9):1279-84 (1999).

- 5 Batimastat, also known as BB-94, is a relatively insoluble chemical having the chemical name [2-*R*-[1(*S**),2*R**,3*S**]]-*N*⁴-hydroxy-*N*¹-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl] butanediamide or (2*S*,-3*R*)-5-methyl-3-[[(*αS*)-*α*-(methylcarbamoyl)phenethyl]carbamoyl]-2-[(2-thienylthio)methyl]hexanohydroxamic acid, and the formula:



10

Other preferred modulators include the tetracyclines, especially minocycline, doxycycline, and COL-3, and steroid inactivators of metalloproteinase translation, such as dexamethasone. See Fife *et al.*, *Cancer Letters* 153(1-2):75-8 (2000); Gilbertson-Beadling *et al.*, *Cancer Chemother. Pharmacol.* 36(5):418-24 (1995); Greenwald *et al.*,
15 *Journal of Rheumatology* 19(6):927-38 (1992); Shapiro *et al.*, *Journal of Immunology* 146(8):2724-29 (1991). A further group of modulators includes DNA binding (minor groove) compounds such as distamycin A and its sulphonic derivatives PNU145156E and PNU153429, anthramycin, pyrrolo[2,1-*c*][1,4]benzodiazepine (PBD) and its methyl esters, and other polypyrrole minor groove binders. See, *e.g.*, Baraldi *et al.*, *Journal of*

Medical Chemistry 42(25):5131-41 (1999); Possati *et al.*, *Clin. Exp. Metastasis* 17(7):575-82 (1999).

The peptide-like modulators comprise a varied class of compounds that includes peptides, peptide mimetics, pseudopeptides, polyamines, and glycosaminoglycans.

- 5 Tissue inhibitors of metalloproteinases (TIMPs) are peptides and polypeptides that inhibit the action of metalloproteinases and that share structural characteristics such as intrachain disulfide bonds. Preferred TIMPs include recombinant and isolated forms of natural TIMPs, including TIMP-1 (a 28.5 kDa polypeptide), TIMP-2 (a 21 kDa polypeptide), and TIMP-3 (a 24-25 kDa polypeptide), and fragments thereof that retain inhibitory function.
- 10 See G. Murphy *et al.*, *Biochemistry* 30(33):8097-102 (1991); A.N. Murphy *et al.*, *Journal of Cell Physiology* 157(2):351-58 (1993); Kishnani *et al.*, *Matrix Biology* 14(6):479-88 (1995).

N-carboxyalkyl peptides are a class of peptides that include

- CH₃CH₂CH₂(R,S)CH(COOH)-NH-Leu-Phe-Ala-NH₂, N-[D,L-2-isobutyl-3(N'-hydroxycarbonylamido)-propanoyl]-O-methyl-L-tyrosine methylamide, and
- 15 HSCH₂CH[CH₂CH(CH₃)₂]CO-Phe-Ala-NH₂ (SIMP). See Fini *et al.*, *Invest. Ophthalmol. Vis. Sci.* 32(11):2997-3001 (1991); Stack *et al.*, *Arch. Biochem. Biophys.* 287(2):240-49 (1991); Wentworth *et al.*, *Invest. Ophthalmol. Vis. Sci.* 33(7):2174-79 (1992). Other peptide-like modulators include polyamines such as alpha-difluoromethylornithine, and
- 20 glycosaminoglycans such as combretastatin and heparin. See Wallon *et al.*, *Mol. Carcinog.* 11(3):138-44 (1994); Dark *et al.*, *Cancer Research* 57 (10):1829-34 (1997); Lyons-Giordano *et al.*, *Exp. Cell Research* 186(1):39-46 (1990).

Sulfur-based modulators such as sulfonanilides and sulfonamides may also be used as modulators. Preferred sulfur-based modulators include sulfonanilide nonsteroidal anti-inflammatory drugs (NSAIDs) such as nimesulide, acyclic sulfonamides, and malonyl alpha-mercaptoketones and alpha-mercaptoalcohols. See, e.g., Bevilacqua *et al.*,
5 *Drugs* 46 Suppl. 1:40-47 (1993); Hanessian *et al.*, *Bioorganic Medical Chemistry Letters* 9(12):1691-96 (1999); Campbell *et al.*, *Bioorganic Medical Chemistry Letters* 8(10):1157-62 (1998).

Another class of modulators includes compounds that antagonize receptors involved in posterior segment ophthalmic disorders, e.g., vascular endothelial growth
10 factor (VEGF) receptors. VEGF antagonists include peptides that inhibit the binding of VEGF to its receptors, such as short disulfide-constrained peptides. See Fairbrother *et al.*, *Biochemistry* 37(51):17754-64 (1998); Binetruy-Tournaire *et al.*, *EMBO J.* 19(7):1525-33 (2000). VEGF antagonists inhibit the outgrowth of blood vessels by inhibiting the ability of VEGF to contact its receptors. This mechanism of anti-
15 angiogenesis operates differently than the mechanism caused by the stimulation of growth factors such as bFGF, which act to inhibit angiogenesis by stimulating native inhibitors of proteases. Other VEGF antagonists may be derived from asymmetric variants of VEGF itself. See, e.g., Siemester *et al.*, *Proceedings of the National Academy of Sciences U.S.A.* 95:4625-29 (1998). Other useful modulators are RNA aptamers, which may be designed
20 to antagonize VEGF or the closely related platelet-derived growth factor (PDGF), and may be administered coupled to polyethylene glycol or lipids. See, e.g., Floege *et al.*, *American Journal of Pathology* 154(1):169-79 (1999); Ostendorf *et al.*, *J. Clin. Invest.* 104(7):913-23 (1999); Willis *et al.*, *Bioconjug. Chem.* 9(5):573-82 (1998).

Modulator screening may be performed by adding a putative modulator test compound to a tissue or cell sample, and monitoring the effect of the test compound on the function and/or expression of optineurin. A parallel sample which does not receive the test compound is also monitored as a control. The treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, and the ability of the cells to interact with other cells or compounds. Differences between treated and untreated cells indicates effects attributable to the test compound.

The invention thus also encompasses methods of screening for agents which inhibit promotion or expression of an optineurin molecule *in vitro*, comprising exposing a cell or tissue in which the optineurin molecule is detectable in cultured cells to an agent in order to determine whether the agent is capable of inhibiting production of the optineurin molecule; and determining the level of optineurin molecule in the exposed cells or tissue, where a decrease in the level of the optineurin molecule after exposure of the cell line to the agent is indicative of inhibition of the optineurin molecule.

Alternatively, the screening method may include *in vitro* screening of a cell or tissue in which an optineurin molecule is detectable in cultured cells to an agent suspected of inhibiting production of the optineurin molecule; and determining the level of the optineurin molecule in the cells or tissue, where a decrease in the level of optineurin molecule after exposure of the cells or tissue to the agent is indicative of inhibition of optineurin molecule production.

20990912600T
The invention also encompasses *in vivo* methods of screening for agents which inhibit expression of the optineurin molecules, comprising exposing a mammal having glaucomatous cells in which an optineurin molecule is detectable to an agent suspected of inhibiting production of the optineurin molecule; and determining the level of optineurin molecule in glaucomatous cells of the exposed mammal. A decrease in the level of optineurin molecule after exposure of the mammal to the agent is indicative of inhibition of marker nucleic acid expression.

Accordingly, the invention provides a method comprising incubating a cell expressing the optineurin molecule with a test compound and measuring the optineurin molecule level. The invention further provides a method for quantitatively determining the level of expression of the optineurin molecule in a cell population, and a method for determining whether an agent is capable of increasing or decreasing the level of expression of the optineurin molecule in a cell population.

The invention also encompasses a method for determining whether an agent is capable of increasing or decreasing the level of expression of the optineurin molecule in a cell population comprises the steps of (a) preparing cell extracts from control and agent-treated cell populations, (b) isolating the optineurin molecule from the cell extracts, (c) quantifying (*e.g.*, in parallel) the amount of an immunocomplex formed between the optineurin molecule and an antibody specific to said optineurin molecule.

mRNA levels can be determined by Northern blot hybridization. mRNA levels can also be determined by methods involving PCR. Other sensitive methods for measuring mRNA, which can be used in high throughput assays, *e.g.*, a method using a DELFIA endpoint detection and quantification method, are described, *e.g.*, in Webb and

Hurskainen *Journal of Biomolecular Screening* 1:119 (1996). Optineurin molecule levels can be determined by immunoprecipitations or immunohistochemistry using an antibody that specifically recognizes the protein product encoded by the nucleic acid molecules.

Agents that are identified as active in the drug screening assay are candidates to be tested for their capacity to block or promote glaucoma.

H. In vivo Methods and Therapeutic Applications

The pharmaceutical compositions of the present invention, including antisense formulations, may be therapeutically used in clinical settings to affect glaucoma. As described above, the optineurin promoter contains response elements which allow for the regulation of optineurin expression, and affecting the activity of a response element can at least partially inhibit or block glaucoma induced in cells by optineurin expression.

As used herein, "at least partially inhibiting" refers to the reduction of a particular event, for example without limitation, the function and/or expression of optineurin polypeptides. In a preferred embodiment, to determine whether a particular event is "at least partially inhibited", the sample of interest subject to a particular method or agent is compared with similar sample of interest not subjected to the particular method or agent. In one embodiment, an inhibition of a particular event is statistically significant. In a particularly preferred embodiment, a particular event is inhibited in a sample of interest by 25%, 50%, 60%, 70%, 75%, 80%, 85%, 90 %, 95% or 100%, as compared to a similar sample of interest not subjected to the particular event. More particularly, as used herein, "blocking" refers to inhibition of a particular event in a sample of interest by greater than 90%, as compared to a similar sample of interest not subject to the particular event.

Accordingly, one aspect of the present invention is directed to the use of optineurin nucleic acid molecules to at least partially inhibit, alter, or retard the development of glaucoma mediated by optineurin. Another aspect of the present invention is directed to the use of antisense optineurin nucleic acid molecules as

5 therapeutic molecules to at least partially inhibit or block (knockdown/knockout) expression of natural optineurin. A further aspect of the present invention is directed to the use of antisense optineurin nucleic acid molecules as therapeutic molecules to at least partially enhance or increase the expression of natural optineurin. The consequence of altering the expression of natural optineurin would be to affect the onset, progression, or

10 development of glaucoma. A particular application would be for the treatment of glaucomas, particularly those where optineurin is expressed at non-normal levels.

In yet another embodiment, a method for at least partially inhibiting the production of an optineurin polypeptide in a cell is provided comprising: (a) providing an isolated nucleic acid molecule comprising at least 10 consecutive nucleotides of the

15 complement of SEQ ID NOs: 3 through 463; (b) introducing the nucleic acid molecule into the cell; and (c) maintaining the cell under conditions permitting the binding of the nucleic acid sequence to optineurin mRNA.

I. Markers

Another subset of the nucleic acid molecules of the invention includes nucleic

20 acid molecules that are markers. As used herein, a “marker” is an indicator for the presence of at least one phenotype or polymorphism, such as single nucleotide polymorphisms (SNPs), cleavable amplified polymorphic sequences (CAPs), amplified fragment length polymorphisms (AFLPs), restriction fragment length polymorphisms

(RFLPs), simple sequence repeats (SSRs), or random amplified polymorphic DNA (RAPDs). The markers can be used in a number of ways in the field of molecular genetics.

In one embodiment of the present invention, the marker specifically hybridizes to
5 a nucleic acid molecule having a nucleic acid sequence selected from the group of SEQ
ID NOs: 1- 463, fragments thereof and complements of either. In a preferred
embodiment, the marker is capable of detecting a SNP set forth in Table 2. In another
preferred embodiment, the marker is capable of acting as a PCR primer to amplify a
region set forth in Table 1. Such markers include nucleic acid molecules SEQ ID NOs: 1-
10 463 or complements thereof or fragments of either that can act as markers and other
nucleic acid molecules of the present invention that can act as markers.

Genetic markers of the invention include “dominant” or “codominant” markers.
“Codominant markers” reveal the presence of two or more alleles (two per diploid
individual) at a locus. “Dominant markers” reveal the presence of only a single allele per
15 locus. The presence of the dominant marker phenotype (*e.g.*, a band of DNA) is an
indication that one allele is in either the homozygous or heterozygous condition. The
absence of the dominant marker phenotype (*e.g.*, absence of a DNA band) is merely
evidence that “some other” undefined allele is present. In the case of populations where
individuals are predominantly homozygous and loci are predominately dimorphic,
20 dominant and codominant markers can be equally valuable. As populations become more
heterozygous and multi-allelic, codominant markers often become more informative of
the genotype than dominant markers. Marker molecules can be, for example, capable of
detecting polymorphisms such as single nucleotide polymorphisms (SNPs).

The genomes of animals and plants naturally undergo spontaneous mutation in the course of their continuing evolution. A "polymorphism" is a variation or difference in the sequence of the gene or its flanking regions that arises in some of the members of a species. The variant sequence and the "original" sequence co-exist in the species' population. In some instances, such co-existence is in stable or quasi-stable equilibrium.

A polymorphism is thus said to be "allelic," in that, due to the existence of the polymorphism, some members of a species may have the original sequence (i.e., the original "allele") whereas other members may have the variant sequence (i.e., the variant "allele"). In the simplest case, only one variant sequence may exist and the polymorphism is thus said to be di-allelic. In other cases, the species' population may contain multiple alleles and the polymorphism is termed tri-allelic, etc. A single gene may have multiple different unrelated polymorphisms. For example, it may have a di-allelic polymorphism at one site and a multi-allelic polymorphism at another site.

The variation that defines the polymorphism may range from a single nucleotide variation to the insertion or deletion of extended regions within a gene. In some cases, the DNA sequence variations are in regions of the genome that are characterized by short tandem repeats (STRs) that include tandem di- or tri-nucleotide repeated motifs of nucleotides. Polymorphisms characterized by such tandem repeats are referred to as "variable number tandem repeat" (VNTR) polymorphisms. VNTRs have been used in identity analysis (EP 370719; U.S. Patent Nos. 5,075,217 and 5,175,082; WO 91/14003).

The detection of polymorphic sites in a sample of DNA may be facilitated through the use of nucleic acid amplification methods. Such methods specifically increase the concentration of polynucleotides that span the polymorphic site, or include that site and

sequences located either distal or proximal to it. Such amplified molecules can be readily detected by gel electrophoresis or other means.

In an alternative embodiment, such polymorphisms can be detected through the use of a marker nucleic acid molecule that is physically linked to such polymorphism(s).

5 For this purpose, marker nucleic acid molecules comprising a nucleotide sequence of a polynucleotide located within 1 mb of the polymorphism(s) and more preferably within 100kb of the polymorphism(s) and most preferably within 10kb of the polymorphism(s) can be employed. Alternatively, marker nucleic acid molecules comprising a nucleotide sequence of a polynucleotide located within 25 cM of the polymorphism(s) and more
10 preferably within 15 cM of the polymorphism(s) and most preferably within 5 cM of the polymorphism(s) can be employed.

The identification of a polymorphism can be determined in a variety of ways. By correlating the presence or absence of it in an organism with the presence or absence of a phenotype, it is possible to predict the phenotype of that organism. If a polymorphism
15 creates or destroys a restriction endonuclease cleavage site, or if it results in the loss or insertion of DNA (*e.g.*, a VNTR polymorphism), it will alter the size or profile of the DNA fragments that are generated by digestion with that restriction endonuclease. As such, organisms that possess a variant sequence can be distinguished from those having the original sequence by restriction fragment analysis. Polymorphisms that can be
20 identified in this manner are termed "restriction fragment length polymorphisms" (RFLPs) (UK Patent Application 2135774; WO 90/13668; WO 90/11369).

Polymorphisms can also be identified by Single Strand Conformation Polymorphism (SSCP) analysis, random amplified polymorphic DNA (RAPD), and

cleaveable amplified polymorphic sequences (CAPS). *See, e.g., Lee et al., Anal. Biochem.* 205:289-293 (1992); Sarkar *et al., Genomics* 13:441-443 (1992); Williams *et al., Nucl. Acids Res.* 18:6531-6535 (1990); and Lyamichev *et al., Science* 260:778-783 (1993). It is understood that one or more of the nucleic acids of the invention, may be
5 utilized as markers or probes to detect polymorphisms by SSCP, RAPD or CAPS analysis.

Polymorphisms may also be found using a DNA fingerprinting technique called amplified fragment length polymorphism (AFLP), which is based on the selective PCR amplification of restriction fragments from a total digest of genomic DNA to profile that
10 DNA. Vos *et al., Nucleic Acids Res.* 23:4407-4414 (1995). This method allows for the specific co-amplification of high numbers of restriction fragments, which can be visualized by PCR without knowledge of the nucleic acid sequence. It is understood that one or more of the nucleic acids of the invention may be utilized as markers or probes to detect polymorphisms by AFLP analysis or for fingerprinting RNA.

15 Single Nucleotide Polymorphisms (SNPs) generally occur at greater frequency than other polymorphic markers and are spaced with a greater uniformity throughout a genome than other reported forms of polymorphism. The greater frequency and uniformity of SNPs means that there is greater probability that such a polymorphism will be found near or in a genetic locus of interest than would be the case for other
20 polymorphisms. SNPs are located in protein-coding regions and noncoding regions of a genome. Some of these SNPs may result in defective or variant protein expression (*e.g.*, as a result of mutations or defective splicing). Analysis (genotyping) of characterized

SNPs can require only a plus/minus assay rather than a lengthy measurement, permitting easier automation.

SNPs can be characterized using any of a variety of methods. Such methods include the direct or indirect sequencing of the site, the use of restriction enzymes, enzymatic and chemical mismatch assays, allele-specific PCR, ligase chain reaction, single-strand conformation polymorphism analysis, single base primer extension (U.S. Patent Nos. 6,004,744 and 5,888,819), solid-phase ELISA-based oligonucleotide ligation assays, dideoxy fingerprinting, oligonucleotide fluorescence-quenching assays, 5'-nuclease allele-specific hybridization TaqMan™ assay, template-directed dye-terminator incorporation (TDI) assay (Chen and Kwok, *Nucl. Acids Res.* 25:347-353, 1997), allele-specific molecular beacon assay (Tyagi *et al.*, *Nature Biotech.* 16: 49-53, 1998), PinPoint assay (Haff and Smirnov, *Genome Res.* 7: 378-388, 1997), dCAPS analysis (Neff *et al.*, *Plant J.* 14:387-392, 1998), pyrosequencing (Ronaghi *et al.*, *Analytical Biochemistry* 267:65-71, 1999; WO 98/13523; WO 98/28440; and www.pyrosequencing.com), using mass spectrometry, *e.g.* the Masscode™ system (WO 99/05319; WO 98/26095; WO 98/12355; WO 97/33000; WO 97/27331; www.rapigene.com; and U.S. Patent No. 5,965,363), invasive cleavage of oligonucleotide probes, and using high density oligonucleotide arrays (Hacia *et al.*, *Nature Genetics* 22:164-167; www.affymetrix.com).

Polymorphisms may also be detected using allele-specific oligonucleotides (ASO), which, can be for example, used in combination with hybridization based technology including Southern, northern, and dot blot hybridizations, reverse dot blot hybridizations and hybridizations performed on microarray and related technology.

10091231.030602

The stringency of hybridization for polymorphism detection is highly dependent upon a variety of factors, including length of the allele-specific oligonucleotide, sequence composition, degree of complementarity (*i.e.* presence or absence of base mismatches), concentration of salts and other factors such as formamide, and temperature. These factors are important both during the hybridization itself and during subsequent washes performed to remove target polynucleotide that is not specifically hybridized. In practice, the conditions of the final, most stringent wash are most critical. In addition, the amount of target polynucleotide that is able to hybridize to the allele-specific oligonucleotide is also governed by such factors as the concentration of both the ASO and the target polynucleotide, the presence and concentration of factors that act to "tie up" water molecules, so as to effectively concentrate the reagents (*e.g.*, PEG, dextran, dextran sulfate, *etc.*), whether the nucleic acids are immobilized or in solution, and the duration of hybridization and washing steps.

Hybridizations are preferably performed below the melting temperature (T_m) of the ASO. The closer the hybridization and/or washing step is to the T_m , the higher the stringency. T_m for an oligonucleotide may be approximated, for example, according to the following formula: $T_m = 81.5 + 16.6 \times (\log_{10}[\text{Na}^+]) + 0.41 \times (\%G+C) - 675/n$; where $[\text{Na}^+]$ is the molar salt concentration of Na^+ or any other suitable cation and n = number of bases in the oligonucleotide. Other formulas for approximating T_m are available and are known to those of ordinary skill in the art.

Stringency is preferably adjusted so as to allow a given ASO to differentially hybridize to a target polynucleotide of the correct allele and a target polynucleotide of the incorrect allele. Preferably, there will be at least a two-fold differential between the

signal produced by the ASO hybridizing to a target polynucleotide of the correct allele and the level of the signal produced by the ASO cross-hybridizing to a target polynucleotide of the incorrect allele (*e.g.*, an ASO specific for a mutant allele cross-hybridizing to a wild-type allele). In more preferred embodiments of the present invention, there is at least a five-fold signal differential. In highly preferred embodiments of the present invention, there is at least an order of magnitude signal differential between the ASO hybridizing to a target polynucleotide of the correct allele and the level of the signal produced by the ASO cross-hybridizing to a target polynucleotide of the incorrect allele. While certain methods for detecting polymorphisms are described herein, other detection methodologies may be utilized.

The identification of a polymorphism in the optineurin gene, or flanking sequences up to about 7,500 bases from either end of the coding region, can be determined in a variety of ways. By correlating the presence or absence of glaucoma in an individual with the presence or absence of a polymorphism in the optineurin gene or its flanking regions, it is possible to diagnose the predisposition (prognosis) of an asymptomatic patient to glaucoma or related diseases.

In accordance with this embodiment of the invention, a sample DNA is obtained from a patient. In a preferred embodiment, the DNA sample is obtained from the patient's blood, however, any source of DNA may be used. The DNA is subjected to restriction endonuclease digestion using the optineurin promoter or fragments thereof as a probe in accordance with the above-described RFLP methods. By comparing the RFLP pattern of the optineurin gene obtained from normal and glaucomatous patients, one can determine a patient's predisposition (prognosis) to glaucoma. The polymorphism

obtained in this approach can then be cloned to identify the mutation at the regulatory region of the gene which affects its expression level. Changes involving promoter interactions with other regulatory proteins can be identified by, for example, gel shift assays using HTM cell extracts, fluid from the anterior chamber of the eye, serum, etc.

5 Several different classes of polymorphisms may be identified through such methods. Examples of such classes include polymorphisms in non-translated optineurin gene sequences, including the promoter or other regulatory regions, and polymorphisms in genes whose products interact with optineurin regulatory sequences.

EXAMPLE 1

10 IDENTIFICATION OF SNPs IN THE OPTINEURIN PROMOTER

To identify novel SNPs in the promoter region up to 5 kb upstream of the transcription initiation site, genomic DNA from 23 individuals is sequenced. The individuals include 7 normal subjects, 8 POAG patients with increased intra-ocular tension, and 8 NTG patients. DNA from these individuals is sequenced over 5000
15 nucleotides. Between 3 and 5 amplicons are required to sequence the optineurin promoter region over 5 kb, which number depends on the number and nature of repetitive sequences and GC richness of the promoter. Each amplicon is sequenced on one or both strands to detect presence of the SNPs.

Amplifications are carried out using a "hot-start" procedure. Samples are
20 processed through 35 cycles of denaturation (95 °C for 30 s) and annealing (55-60 °C for 30 s), followed by one last step of elongation (72 °C for 50 s). PCR products are diluted in 5 volumes of Qiagen PB buffer (Qiagen, Valencia, California), transferred onto a Whatman GF/C filter plate (Whatman Group, Ann Arbor Michigan), washed two times

with an 80% ethanol 20mM Tris pH 7.5, and eluted in 50 microliters of water. Samples are quantified using the PicoGreen reagent protocol (Molecular Probes, Eugene, Oregon).

A second PCR is performed on an Applied Biosystem Gene Amp PCR System 9700 (96 wells) or 9700 Viper (384 wells)(Applied Biosystem, Foster City, California) to

- 5 incorporate the sequencing dyes using a protocol of 25 cycles of denaturation (95 °C for 10 s) and annealing (55 °C for 5 s), followed by one last step of elongation (59 °C for 2 min). PCR products are purified by the ABI ethanol-EDTA precipitation protocol, collected in a Beckman-Couter Allegra 6R centrifuge (Beckman-Coulter, Inc., Fullerton, California) and resuspended in a 50% HiDi-formamide solution. Samples are run on an
- 10 Applied Biosystems 3700 DNA Analyser automated sequencer.

- Sequence data is analyzed with the Staden preGap4 and Gap4 programs Griffen, *Computer Analysis of Sequence, Part 1* (Humana Press, 1994). Sequencing data and all patients' information is stored in a 4D database on a MacIntosh G4. Data is transferred from the 4D database to SUN computers using CAP AppleShare server software. Several
- 15 SNPs are identified in the promoter region and their allelic frequencies in patients and controls are calculated (Table 4). Genotypic frequencies may also be calculated for identified SNPs (Table 5).

Table 4: SNPs and Allelic Frequencies

Location [†]	CN*	Number of Subjects	Allelic Frequency of Variant		
			POAG Patients	NTG Patients	Normal (control)
391	a / g	27	3/10 (30%)	5/8 (62.5%)	3/9 (33%)
709	g / a	29	3/10 (30.0%)	1/10 (10.0 %)	0/8 (0%)
887	t / a	29	1/11 (9.1%)	0/10 (0%)	0/8 (0%)

† Location in SEQ ID NO: 1; * Characteristic Nucleotides

Table 5: Genotypic Frequencies for an Optineurin Promoter SNP

SNP Location [†] & CN*	Subject Group	Genotypic Frequencies		
		aa	ag	gg
2606 a / g	POAG Patients (n=11)	1 (9.1)	9 (81.8%)	1 (9.1)
	NTG Patients (n=11)	2 (18.2%)	7 (63.6%)	2 (18.2%)
	Normal (control) (n=7)	1 (24.3%)	5 (71.4%)	1 (24.3%)

[†] Location in SEQ ID NO: 1; * Characteristic Nucleotides

EXAMPLE 2

VECTOR CONSTRUCTION

Expression vectors can be constructed for efficient expression of an optineurin promoter construct (e.g., the optineurin promoter operably linked to a heterologous nucleic acid, *etc.*) in mammalian cell lines. These expression vectors generally include the optineurin promoter operably linked to a nucleic acid sequence. The vectors can also be designed to confer antibiotic or toxin resistance through expression of resistance genes under control of a second promoter. Illustrative vectors include pcDNA3.1 and pMEP4 (Invitrogen, Carlsbad, California).

For example, the CMV2 promoter is deleted from mammalian vector pTracer CMV2 (Invitrogen) and replaced with a nucleic acid molecule having SEQ ID NO: 1 linked in a manner that facilitates expression of the green florescent protein (pTrOp). Chinese hamster ovary cells (CHO) are then transfected with either pTracer CMV2 or pTrOp using the method set forth in Cameri *et al.*, *Nature Biotechnology* 14: 315-319 (1996). Levels of green fluorescent protein are measured using the method set forth in Cameri *et al.*, *Nature Biotechnology* 14: 315-319 (1996).

EXAMPLE 3

MODULATOR SCREENING

5

The transfected cell lines described in Example 2 containing either pTracer CMV2 or pTrOp are grown in a cell medium described by Miller *et al. J. Biol. Chem.* 274 20465-20472 (1999) supplemented by a test compound. The level of green fluorescent protein is measured using the method set forth in Cameri *et al., Nature* 10 *Biotechnology* 14: 315-319 (1996) across a range of test compounds and effective concentrations in the CHO cell lines containing either pTracer CMV2 or pTrOp.

All references, publications, and patents cited herein are specifically incorporated by reference in a manner consistent with this disclosure. Reagents and compositions (e.g., nucleic acid molecule, amino acid molecules, vectors, host cells, antibodies, *etc.*) 15 related to optineurin can be made using methodologies known to those of skill in the art or may be obtained from commercial suppliers.